Researchers Database

shirai katsuyuki

    Radiology Professor
Last Updated :2021/10/17

Researcher Information

J-Global ID

Research Areas

  • Life sciences / Tumor diagnostics and therapeutics

Academic & Professional Experience

  • Gunma University Research Center for Heavy Particle Beam Medicine
  • Gunma University

Published Papers

  • Keiko Akahane, Katsuyuki Shirai, Masaru Wakatsuki, Kazunari Ogawa, Kyosuke Minato, Kohei Hamamoto, Satoru Takahashi, Koichi Suzuki, Jun Takahashi, Toshiki Rikiyama, Keita Matsumoto, Hirosato Mashima
    Clinical case reports 8 (5) 919 - 922 2020/05 [Refereed][Not invited]
     
    Antiangiogenic agents, such as ramucirumab, should be cautiously administered along with radiotherapy because of the enhanced risk of adverse events.
  • Yukihiro Takayasu, Nobuteru Kubo, Masato Shino, Osamu Nikkuni, Shota Ida, Atsushi Musha, Katsumasa Takahashi, Junko Hirato, Katsuyuki Shirai, Jun-Ichi Saitoh, Satoshi Yokoo, Kazuaki Chikamatsu, Tatsuya Ohno, Takashi Nakano
    Cancer medicine 8 (17) 7227 - 7235 2019/12 [Refereed][Not invited]
     
    This study aimed to evaluate the efficacy of carbon-ion radiotherapy in combination with chemotherapy using dacarbazine, nimustine, and vincristine (DAV therapy) in mucosal melanoma. Twenty-one patients with clinically localized mucosal melanoma of the head and neck were enrolled. The primary endpoint was 3-year overall survival (OS). Secondary endpoints included local control, progression-free survival (PFS), and adverse event occurrence. Carbon-ion radiotherapy with a dose of 57.6-64.0 Gy (relative biological effectiveness) in 16 fractions was delivered concurrently with DAV therapy, and 2 cycles of adjuvant DAV therapy were administered every 6 weeks. The median follow-up periods were 15.5 months for all patients, and 31.2 months for 12 surviving patients. All patients had locally advanced T4a or T4b disease in the rhino-sinus area. In 16 patients (76.2%), 3 cycles of planned DAV therapy were completed. The 3-year OS and PFS rates were 49.2% and 37.0% respectively. The 3-year local control rate was 92.3%. Eleven patients (52%) developed distant metastasis, which was the most frequent pattern of the first failure. Commonly presenting acute grade 2-3 toxicities associated with radiotherapy and chemotherapy were mucositis (11 patients [53%]) and leukopenia (9 patients [43%]), which improved with conservative therapy. None of the patients developed grade 3 or greater late toxicities. Carbon-ion radiotherapy in combination with DAV therapy led to excellent local control for advanced mucosal melanoma within acceptable toxicities. The efficacy of additional DAV therapy in improving survival was weaker than expected as distant metastases still occurred frequently. Trial registration no. UMIN000007939.
  • Masahiro Ashizawa, Yu Akahoshi, Hirofumi Nakano, Shunto Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Kazuki Yoshimura, Ayumi Gomyo, Masaharu Tamaki, Machiko Kusuda, Kazuaki Kameda, Hidenori Wada, Koji Kawamura, Miki Sato, Kiriko Terasako-Saito, Aki Tanihara, Shun-Ichi Kimura, Hideki Nakasone, Shinichi Kako, Keiko Akahane, Masaru Wakatsuki, Katsuyuki Shirai, Yoshinobu Kanda
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 25 (12) 2461 - 2467 1083-8791 2019/12 [Refereed][Not invited]
     
    Myeloablative conditioning regimens are associated with severe gonadal toxicity. To preserve ovarian function, we have been investigating ovarian shielding during total body irradiation (TBI) with a myeloablative dose. In this report, we update the clinical outcomes. Female patients with standard-risk hematologic diseases, aged 40 years or younger, who desired to have children, were included (n = 19). The conditioning regimen consisted of TBI at 12 Gy with ovarian shielding and cyclophosphamide (120 mg/kg) or cytarabine (24 g/m2). Ovarian shielding reduced the actual irradiation dose applied to the ovaries from 12 Gy to 2 to 3 Gy. The median age at hematopoietic stem cell transplantation (HSCT) was 24 years (range, 19 to 33 years). With a median follow-up period of 1449 days (range, 64 to 3694) after HSCT, 5-year overall survival and 1- and 5-year relapse rates were 67%, 17%, and 31%, respectively. Only 2 of 14 patients with acute myeloid or lymphoid leukemia in remission have relapsed thus far. The 6-month and 1-year cumulative rates of menstrual recovery were 42% and 78%, respectively. In all patients with menstrual recovery, menstruation recovered within 1 year. The serum anti-Müllerian hormone (AMH) level tended to gradually increase after menstrual recovery. Three patients with extensive chronic graft-versus-host disease experienced delayed recovery of menstruation and serum AMH. Five pregnancies in 3 patients resulted in normal delivery in 1, selective cesarean operation in 1, current pregnancy in 1, and natural abortion in 2. These results suggest that a myeloablative TBI regimen with ovarian shielding could preserve fertility after HSCT without an apparent increase in relapse in standard-risk patients. Because serum AMH recovered gradually over time, the AMH level during the early phase after HSCT may have little value as a marker of ovarian reserve.
  • Nobuteru Kubo, Yoshiki Kubota, Hidemasa Kawamura, Takahiro Oike, Makoto Sakai, Takuya Kumazawa, Yuhei Miyasaka, Shohei Okazaki, Daijiro Kobayashi, Hiro Sato, Tatsuji Mizukami, Atsushi Musha, Katsuyuki Shirai, Jun-ichi Saitoh, Satoshi Yokoo, Kazuaki Chikamatsu, Tatsuya Ohno, Takashi Nakano
    Radiotherapy and Oncology Elsevier {BV} 2019/08 [Refereed][Not invited]
  • Shirai K, Ohno T, Saitoh JI, Okamoto M, Katoh H, Murata K, Kawamura H, Musha A, Abe T, Mizukami T, Akahane K, Nakano T
    Frontiers in oncology 9 181  2019 [Refereed][Not invited]
  • Shirai K, Kubota Y, Ohno T, Saitoh JI, Abe T, Mizukami T, Mori Y, Kawamura H, Akahane K, Nakano T
    Frontiers in oncology 9 731  2019 [Refereed][Not invited]
  • Kaira K, Ono A, Kamide Y, Sunaga N, Koga Y, Saitoh JI, Shirai K, Ebara T, Hisada T, Ishizuka T
    Journal of radiation research 0449-3060 2018/11 [Refereed][Not invited]
  • Jun-Ichi Saitoh, Katsuyuki Shirai, Takanori Abe, Nobuteru Kubo, Takeshi Ebara, Tatsuya Ohno, Koichi Minato, Ryusei Saito, Masanobu Yamada, Takashi Nakano
    Anticancer Research 38 (2) 885 - 891 1791-7530 2018/02 [Refereed][Not invited]
     
    Background/Aim: The aim of this study was to assess the feasibility and safety of hypofractionated carbon-ion radiotherapy (C-ion RT) in patients with stage III non-small cell lung cancer (NSCLC). Patients and Methods: Patients with untreated, histologically proven, unresectable stage III NSCLC and not candidates for chemotherapy were included in this study. C-ion RT was planned and administered with 4 Gy (relative biological effectiveness (RBE)) in daily fractions for a total dose of 64 Gy (RBE) without combined chemotherapy. Dose-limiting toxicity (DLT) was defined as suspension of C-ion RT treatment for 2 weeks due to ≥ grade 2 pneumonitis, or any other ≥ grade 3 adverse event, or as any ≥ grade 4 adverse event within 3 months from the start of treatment. Results: Six patients were treated between June 2013 and December 2014. The planned full dose of C-ion RT (64 Gy (RBE)) was completed in all patients. No patient developed DLT, and no patient experienced toxicities of ≥grade 3 severity. The overall response rate was 100%, and local tumor control was achieved in all patients during the survival period. Conclusion: Hypofractionated C-ion RT of patients with stage III NSCLC was feasible and well tolerated. Although the number of patients in this study was small, the results support further investigations to confirm the long-term therapeutic efficacy of this treatment.
  • Katsuyuki Shirai, Jun-ichi Saitoh, Atsushi Musha, Takanori Abe, Daijiro Kobayashi, Takeo Takahashi, Tomoaki Tamaki, Hidemasa Kawamura, Yukihiro Takayasu, Masato Shino, Minoru Toyoda, Katsumasa Takahashi, Junko Hirato, Satoshi Yokoo, Kazuaki Chikamatsu, Tatsuya Ohno, Tatsuya Nakano
    CANCER SCIENCE 108 (10) 2039 - 2044 1349-7006 2017/10 [Refereed][Not invited]
     
    To evaluate the efficacy and safety of carbon-ion radiotherapy for non-squamous cell carcinoma of the head and neck, 35 patients were enrolled in this prospective study. The primary end-point was the 3-year local control rate, and the secondary end-points included the 3-year overall survival rate and adverse events. Acute and late adverse events were evaluated according to the Common Terminology Criteria for Adverse Events, version 4.0. The median follow-up time for all patients was 39months. Thirty-two and three patients received 64.0Gy (relative biological effectiveness) and 57.6Gy (relative biological effectiveness) in 16 fractions, respectively. Adenoid cystic carcinoma was dominant (60%). Four patients had local recurrence and five patients died. The 3-year local control and overall survival rates were 93% and 88%, respectively. Acute grade 2-3 radiation mucositis (65%) and dermatitis (31%) was common, which improved immediately with conservative therapy. Late mucositis of grade 2, grade 3, and grade 4 were observed in 11, one, and no patients, respectively. There were no adverse events of grade 5. Carbon-ion radiotherapy achieved excellent local control and overall survival rates for non-squamous cell carcinoma. However, the late mucosal adverse events were not rare, and meticulous treatment planning is required. Trial registration no. UMIN000007886.
  • Katsuyuki Shirai, Jun-Ichi Saitoh, Atsushi Musha, Takanori Abe, Daijiro Kobayashi, Takeo Takahashi, Tomoaki Tamaki, Hidemasa Kawamura, Yukihiro Takayasu, Masato Shino, Minoru Toyoda, Katsumasa Takahashi, Junko Hirato, Satoshi Yokoo, Kazuaki Chikamatsu, Tatsuya Ohno, Tatsuya Nakano
    Cancer science 108 (10) 2039 - 2044 1347-9032 2017/10 [Refereed][Not invited]
     
    To evaluate the efficacy and safety of carbon-ion radiotherapy for non-squamous cell carcinoma of the head and neck, 35 patients were enrolled in this prospective study. The primary end-point was the 3-year local control rate, and the secondary end-points included the 3-year overall survival rate and adverse events. Acute and late adverse events were evaluated according to the Common Terminology Criteria for Adverse Events, version 4.0. The median follow-up time for all patients was 39 months. Thirty-two and three patients received 64.0 Gy (relative biological effectiveness) and 57.6 Gy (relative biological effectiveness) in 16 fractions, respectively. Adenoid cystic carcinoma was dominant (60%). Four patients had local recurrence and five patients died. The 3-year local control and overall survival rates were 93% and 88%, respectively. Acute grade 2-3 radiation mucositis (65%) and dermatitis (31%) was common, which improved immediately with conservative therapy. Late mucositis of grade 2, grade 3, and grade 4 were observed in 11, one, and no patients, respectively. There were no adverse events of grade 5. Carbon-ion radiotherapy achieved excellent local control and overall survival rates for non-squamous cell carcinoma. However, the late mucosal adverse events were not rare, and meticulous treatment planning is required. Trial registration no. UMIN000007886.
  • Katsuyuki Shirai, Kyohei Fukata, Akiko Adachi, Jun-ichi Saitoh, Atsushi Musha, Takanori Abe, Tatsuaki Kanai, Daijiro Kobayashi, Yuka Shigeta, Satoshi Yokoo, Kazuaki Chikamatsu, Tatsuya Ohno, Takashi Nakano
    RADIOTHERAPY AND ONCOLOGY 125 (1) 36 - 40 0167-8140 2017/10 [Refereed][Not invited]
     
    Background and purpose: We aimed to evaluate the relationship between brainstem necrosis and dose volume histograms in patients with head and neck tumors after carbon-ion radiotherapy. Material and methods: We evaluated 85 patients with head and neck tumors who underwent carbon-ion radiotherapy and were followed-up for >= 12 months. Brainstem necrosis was evaluated using the Common Terminology Criteria for Adverse Events (version 4.0). Results: The median follow-up was 24 months, and four patients developed grade 1 brainstem necrosis, with 2-year and 3-year cumulative rates of 2.8% and 6.5%, respectively. Receiver operating characteristic curve analysis revealed the following significant cut-off values: a maximum brainstem dose of 48 Gy (relative biological effectiveness [RBE]), D1 cm(3) of 27 Gy (RBE), V40 Gy (RBE) of 0.1 cm(3), V30 Gy (RBE) of 0.7 cm(3), and V20 Gy (RBE) of 1.4 cm(3). Multivariate analysis revealed that V30 Gy (RBE) was most significantly associated with brainstem necrosis. The 2-year cumulative rates were 33% and 0% for V30 Gy (RBE) of >= 0.7 cm(3) and <0.7 cm(3), respectively (p < 0.001). Conclusions: The present study indicated that the dose constraints might help minimize brainstem necrosis after carbon-ion radiotherapy. (C) 2017 The Author(s). Published by Elsevier Ireland Ltd.
  • Shintaro Shiba, Jun-Ichi Saitoh, Daisuke Irie, Katsuyuki Shirai, Takanori Abe, Yoshiki Kubota, Makoto Sakai, Ryosuke Okada, Tatsuya Ohno, Takashi Nakano
    ANTICANCER RESEARCH 37 (10) 5673 - 5680 0250-7005 2017/10 [Refereed][Not invited]
     
    Background/Aim: To analyze the accuracy of patient positioning and dose distribution quality using a fiducial marker-matching technique in carbon-ion radiotherapy (C-ion RT) for stage I lung cancer. Patients and Methods: Thirteen patients with 26 fiducial markers and 104 radiation fields were examined. Change in the fiducial marker position coordinates from the gross tumor volume center (Delta m), and change in the water-equivalent path length of the chest wall (Delta WEL) were measured in each radiation field. Criterion for an acceptable change in dose distribution was defined as the percentage of D95 (% D95) at gross tumor volume greater than 90% of the prescribed dose. Results: Thirteen radiation fields (12.5%) were classified as unacceptable. Delta m and Delta WEL had significant negative correlations with % D95 and thus were significant factors related to unacceptable irradiation fields. Conclusion: Patient positioning using a fiducial marker-matching technique resulted in 12.5% of radiation fields demonstrating unacceptable degradation due to Delta m and Delta WEL.
  • Sakai M, Kubota Y, Saitoh JI, Irie D, Shirai K, Okada R, Torikoshi M, Ohno T, Nakano T
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 0167-8140 2017/10 [Refereed][Not invited]
  • Katsuyuki Shirai, Masashi Koto, Yusuke Demizu, Hiroaki Suefuji, Tatsuya Ohno, Hiroshi Tsuji, Tomoaki Okimoto, Yoshiyuki Shioyama, Jun-ichi Saitoh, Kenji Nemoto, Takashi Nakano, Tadashi Kamada
    CANCER SCIENCE 108 (7) 1447 - 1451 1349-7006 2017/07 [Refereed][Not invited]
     
    This study aimed to evaluate the clinical outcomes of patients with mucoepidermoid carcinomas in the head and neck treated with carbon-ion radiotherapy. Data from 26 patients who underwent carbon-ion radiotherapy in four facilities were analyzed in this multi-institutional retrospective study: the Japan Carbon-ion Radiation Oncology Study Group. The median follow-up time was 34 months. One patient experienced local recurrence, and the 3-year local control rate was 95%. One patient developed lymph node recurrence and five developed distant metastases. The 3-year progression-free survival rate was 73%. Five patients died, two of mucoepidermoid carcinoma and three of intercurrent disease. The 3-year overall survival rate was 89%. Acute mucositis and dermatitis of grade 3 or higher were experienced by 19% and 8% of patients, respectively; these improved with conservative therapy. Late mucositis and osteonecrosis of jaw were observed in 12% and 23% of patients, respectively. The 3-year cumulative rate of any late adverse event of grade 3 or higher was 14%. None of the patients died of the acute or late adverse events. Carbon-ion radiotherapy was efficacious and safe for treating mucoepidermoid carcinoma in this multi-institutional retrospective study (registration no. UMIN000024473). We are currently undertaking a prospective multicenter study.
  • Katsuyuki Shirai, Masashi Koto, Yusuke Demizu, Hiroaki Suefuji, Tatsuya Ohno, Hiroshi Tsuji, Tomoaki Okimoto, Yoshiyuki Shioyama, Jun-Ichi Saitoh, Kenji Nemoto, Takashi Nakano, Tadashi Kamada, The Japan Carbon-Ion Radiation Oncology Study Group
    Cancer Science 108 (7) 1447 - 1451 1349-7006 2017/07 [Refereed][Not invited]
     
    This study aimed to evaluate the clinical outcomes of patients with mucoepidermoid carcinomas in the head and neck treated with carbon-ion radiotherapy. Data from 26 patients who underwent carbon-ion radiotherapy in four facilities were analyzed in this multi-institutional retrospective study: the Japan Carbon-ion Radiation Oncology Study Group. The median follow-up time was 34 months. One patient experienced local recurrence, and the 3-year local control rate was 95%. One patient developed lymph node recurrence and five developed distant metastases. The 3-year progression-free survival rate was 73%. Five patients died, two of mucoepidermoid carcinoma and three of intercurrent disease. The 3-year overall survival rate was 89%. Acute mucositis and dermatitis of grade 3 or higher were experienced by 19% and 8% of patients, respectively these improved with conservative therapy. Late mucositis and osteonecrosis of jaw were observed in 12% and 23% of patients, respectively. The 3-year cumulative rate of any late adverse event of grade 3 or higher was 14%. None of the patients died of the acute or late adverse events. Carbon-ion radiotherapy was efficacious and safe for treating mucoepidermoid carcinoma in this multi-institutional retrospective study (registration no. UMIN000024473). We are currently undertaking a prospective multicenter study.
  • Katsuyuki Shirai, Takanori Abe, Jun-Ichi Saitoh, Tatsuji Mizukami, Daisuke Irie, Yosuke Takakusagi, Shintaro Shiba, Naoko Okano, Takeshi Ebara, Tatsuya Ohno, Takashi Nakano
    ONCOLOGY LETTERS 13 (6) 4420 - 4426 1792-1074 2017/06 [Refereed][Not invited]
     
    The present study (University Hospital Medical Information Network study no. UMIN000003797) aimed to evaluate whether the maximum standardized uptake value (SUVmax) of pretreatment F-18-fluorodeoxyglucose-positron emission tomography (FDG-PET) is prognostic factor for stage I non-small cell lung cancer (NSCLC) treated with carbon ion radiotherapy (C-ion RT). Patients treated between June 2010 and June 2013 at Gunma University Heavy Ion Medical Center (Maebashi, Japan) on a prospective protocol were included in the present study. Patients with T1a-b and T2a NSCLC were treated with C-ion RT at a dose of 52.8 Gy [relative biological effectiveness (RBE)] and 60.0 Gy (RBE), respectively, in four fractions. Prior to treatment, all patients underwent FDG-PET, in which the SUVmax of primary tumors was evaluated. Local control, progression-free survival (PFS), and overall survival (OS) were calculated. A total of 45 patients were analyzed and the median follow-up period was 28.9 months. The 2-year local control, PFS and OS rates for all patients were 93, 78 and 89%, respectively. The mean SUVmax of primary tumors was 5.5, and patients were divided into higher (>= 5.5) and lower (<5.5) SUVmax groups. The 2-year PFS rates were 61 and 89% for the higher and lower SUVmax groups, respectively (P=0.01), and the 2-year OS rates for the higher and lower SUVmax groups were 76 and 96%, respectively (P=0.01). The higher SUVmax group exhibited a significantly worse PFS and OS compared with the lower SUVmax group; however, the SUVmax was not associated with the local control rate. In total, 2 patients (4%) experienced grade 2 or 3 radiation pneumonitis, with their symptoms improved through conservative treatment. No patients experienced any grade 4 or 5 toxicities. The results of the present study indicate that pretreatment SUVmax is a prognostic indicator for outcomes in patients with stage I NSCLC treated with C-ion RT.
  • Katsuyuki Shirai, Motohiro Kawashima, Jun-ichi Saitoh, Takanori Abe, Kyohei Fukata, Yuka Shigeta, Daisuke Irie, Shintaro Shiba, Naoko Okano, Tatsuya Ohno, Takashi Nakano
    PLOS ONE 12 (4) e0175589  1932-6203 2017/04 [Refereed][Not invited]
     
    The safety and efficacy of carbon-ion radiotherapy for advanced non-small cell lung cancer have not been established. We evaluated the clinical outcomes and dose-volume histogram parameters of carbon-ion radiotherapy compared with photon therapy in T2b-4N0M0 non-small cell lung cancer. Twenty-three patients were treated with carbon-ion radiotherapy between May 2011 and December 2015. Seven, 14, and 2 patients had T2b, T3, and T4, respectively. The median age was 78 (range, 53-91) years, with 22 male patients. There were 12 adenocarcinomas, 8 squamous cell carcinomas, 1 non-small cell lung carcinoma, and 2 clinically diagnosed lung cancers. Eleven patients were operable, and 12 patients were inoperable. Most patients (91%) were treated with carbon-ion radiotherapy of 60.0 Gy relative biological effectiveness (RBE) in 4 fractions or 64.0 Gy (RBE) in 16 fractions. Local control and overall survival rates were calculated. Dose-volume histogram parameters of normal lung and tumor coverages were compared between carbon-ion radiotherapy and photon therapies, including three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT). The median follow-up of surviving patients was 25 months. Three patients experienced local recurrence, and the 2-year local control rate was 81%. During follow-up, 5 patients died of lung cancer, and 1 died of intercurrent disease. The 2-year overall survival rate was 70%. Operable patients had a better overall survival rate compared with inoperable patients (100% vs. 43%; P = 0.04). There was no grade >= 2 radiation pneumonitis. In dose-volume histogram analysis, carbon-ion radiotherapy had a significantly lower dose to normal lung and greater tumor coverage compared with photon therapies. Carbon-ion radiotherapy was effectively and safely performed for T2b-4N0M0 non-small cell lung cancer, and the dose distribution was superior compared with those for photon therapies. A Japanese multi-institutional study is ongoing to prospectively evaluate these patients and establish the use of carbon-ion radiotherapy.
  • Jun-ichi Saitoh, Katsuyuki Shirai, Masumi Imaeda, Atsushi Musha, Takanori Abe, Masato Shino, Yukihiro Takayasu, Katsumasa Takahashi, Kazuaki Chikamatsu, Takashi Nakano
    RADIATION ONCOLOGY 12 (1) 39  1748-717X 2017/02 [Refereed][Not invited]
     
    Background: To assess the efficacy of concurrent chemoradiotherapy (CCRT) with daily low-dose cisplatin (CDDP) plus weekly docetaxel (DTX) for patients with T2N0 glottic cancer. Methods: Between January 2004 and December 2013, 62 treatment-naive patients with histologically proven T2N0 glottic cancer were treated with concurrent chemoradiotherapy. Radiation therapy (RT; 2 Gy daily fractions up to a total dose of 66 Gy) was administered in combination with daily low-dose CDDP (6 mg/m(2), five times a week), plus weekly DTX (10 mg/m(2)) for up to 4 weeks from the commencement of RT. Results: Median duration of follow-up was 70 months. The actuarial 3-year and 5-year overall survival rates were 95% and 93%. The 3-year and 5-year cause-specific survival rates were both 100%. The actuarial 3-year and 5-year local control rates were 94% and 94%, respectively. Hematologic toxicity (neutoropenia of severity >= Grade 3) was observed in 8% of the patients, and non-hematologic toxicity (radiation mucositis of severity >= Grade 3) developed in one patient (2%). Radiation dermatitis of severity >= Grade 3 and laryngeal necrosis developed in one patient. Conclusion: CCRT with weekly DTX and low-dose CDDP appears to be a practical and safe modality and is expected to improve local control.
  • Daisuke Irie, Jun-ichi Saitoh, Katsuyuki Shirai, Takanori Abe, Yoshiki Kubota, Makoto Sakai, Shin-ei Noda, Tatsuya Ohno, Takashi Nakano
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 96 (5) 1117 - 1123 0360-3016 2016/12 [Refereed][Not invited]
     
    Purpose: To evaluate robustness of dose distribution of carbon-ion radiation therapy (C-ion RT) in non-small cell lung cancer (NSCLC) and to identify factors affecting the dose distribution by simulated dose distribution. Methods and Materials: Eighty irradiation fields for delivery of C-ion RT were analyzed in 20 patients with stage I NSCLC. Computed tomography images were obtained twice before treatment initiation. Simulated dose distribution was reconstructed on computed tomography for confirmation under the same settings as actual treatment with respiratory gating and bony structure matching. Dose-volume histogram parameters, such as %D95 (percentage of D95 relative to the prescribed dose), were calculated. Patients with any field for which the %D95 of gross tumor volume (GTV) was below 90% were classified as unacceptable for treatment, and the optimal target margin for such cases was examined. Results: Five patients with a total of 8 fields (10% of total number of fields analyzed) were classified as unacceptable according to %D95 of GTV, although most patients showed no remarkable change in the dose-volume histogram parameters. Receiver operating characteristic curve analysis showed that tumor displacement and change in water-equivalent pathlength were significant predictive factors of unacceptable cases (P<.001 and P=.002, respectively). The main cause of degradation of the dose distribution was tumor displacement in 7 of the 8 unacceptable fields. A 6-mm planning target volume margin ensured a GTV %D95 of >90%, except in 1 extremely unacceptable field. Conclusions: According to this simulation analysis of C-ion RT for stage I NSCLC, a few fields were reported as unacceptable and required resetting of body position and reconfirmation. In addition, tumor displacement and change in water-equivalent
  • Katsuyuki Shirai, Jun-Ichi Saitoh, Atsushi Musha, Takanori Abe, Daijiro Kobayashi, Yosuke Takakusagi, Yukihiro Takaysu, Masato Shino, Minoru Toyoda, Katsumasa Takahashi, Kazuaki Chikamatsu, Tatsuya Ohno, Takashi Nakano
    ANTICANCER RESEARCH 36 (12) 6571 - 6578 0250-7005 2016/12 [Refereed][Not invited]
     
    Background: Hypopharyngeal cancer is relatively rare disease and continues to have a poor prognosis. This study analyzed the efficacy and safety of radiotherapy for stage I-IVB hypopharyngeal cancer. Patients and Methods: Between 2000 and 2015, 72 patients were treated with definitive radiotherapy and 29 patients with stage IVA were treated with postoperative radiotherapy. Results: With definitive radiotherapy, the 3-year locoregional control rates for stage I-II, III, IVA, and IVB disease were 89%, 74%, 51% and 0%, respectively. The 3-year overall survival rates for patients with stage I-II, III, IVA and IVB disease were 84%, 89%, 55% and 15%, respectively. In patients with stage IVA disease treated with postoperative radiotherapy, 3-year locoregional control and overall survival rates were 83% and 75%, respectively, which were significantly better than those treated with definitive radiotherapy. Conclusion: Definitive radiotherapy was effective for stage I-III disease. Surgery and postoperative radiotherapy improved the survival rate of patients with stage IVA hypopharyngeal cancer.
  • Musha A, Saitoh JI, Shirai K, Yokoo S, Ohno T, Nakano T
    Journal of medical case reports 10 (1) 284  2016/10 [Refereed][Not invited]
  • DAV化学療法併用重粒子線照射による鼻副鼻腔悪性黒色腫の治療成績
    高橋 克昌, 岡本 彩子, 新國 摂, 近松 一朗, 白井 克幸, 齋藤 淳一, 大野 達也, 中野 隆史
    日本鼻科学会会誌 (一社)日本鼻科学会 55 (3) 484 - 484 0910-9153 2016/09 [Refereed][Not invited]
  • Nobuteru Kubo, Jun-Ichi Saitoh, Hirofumi Shimada, Katsuyuki Shirai, Hidemasa Kawamura, Tatsuya Ohno, Takashi Nakano
    Journal of Radiation Research 57 (5) 548 - 554 1349-9157 2016/09 [Refereed][Not invited]
     
    The present study compared the dose-volume histograms of patients with Stage IIIA non-small cell lung cancer (NSCLC) treated with carbon ion radiotherapy with those of patients treated with X-ray radiotherapy. Patients with Stage IIIA NSCLC (n = 10 patients for each approach) were enrolled. Both radiotherapy plans were calculated with the same targets and organs at risk on the same CT. The treatment plan for the prophylactic lymph node and primary tumor (PTV1) delivered 40 Gy for X-ray radiotherapy and 40 Gy (relative biological effectiveness RBE) for carbon ion radiotherapy. The total doses for the primary tumor and clinically positive lymph nodes (PTV2) were 60 Gy for X-ray radiotherapy and 60 Gy (RBE) for carbon ion radiotherapy. The homogeneity indexes for PTV1 and PTV2 were superior for carbon ion radiotherapy in comparison with X-ray radiotherapy (PTV1, 0.57 vs 0.65, P = 0.009 PTV2, 0.07 vs 0.16, P = 0.005). The normal lung mean dose, V5, V10 and V20 for carbon ion radiotherapy were 7.7 Gy (RBE), 21.4%, 19.7% and 17.0%, respectively, whereas the corresponding doses for X-ray radiotherapy were 11.9 Gy, 34.9%, 26.6% and 20.8%, respectively. Maximum spinal cord dose, esophageal maximum dose and V50, and bone V10, V30 and V50 were lower with carbon ion radiotherapy than with X-ray radiotherapy. The present study indicates that carbon ion radiotherapy provides a more homogeneous target dose and a lower dose to organs at risk than X-ray radiotherapy for Stage IIIA non-small cell lung cancer.
  • Takanori Abe, Katsuyuki Shirai, Jun-Ichi Saitoh, Takeshi Ebara, Hirofumi Shimada, Mutsumi Tashiro, Naoko Okano, Tatsuya Ohno, Takashi Nakano
    ACTA ONCOLOGICA 55 (2) 163 - 166 0284-186X 2016/02 [Refereed][Not invited]
     
    Background: The purpose of this study was to assess the incidence, risk factors, and dose-volume relationship of radiation-induced rib fracture (RIRF) after carbon ion radiotherapy for lung cancer.Material and methods: Fifty-seven ribs of 18 patients with peripheral stage I non-small cell lung cancer treated with carbon ion radiotherapy were analyzed on rib fracture. The patients were treated at a total dose of 52.8 Gy [relative biologic effectiveness (RBE)] or 60.0 Gy (RBE) in 4 fractions and were followed at least six months. Patient characteristics and dosimetric parameters were analyzed for associations with RIRF.Results: Eighteen patients and 57 ribs were included in this study. The median length of follow-up was 36.5 months. RIRF was observed in seven (39%) of the 18 patients, and in 11 (19%) of 57 ribs. Only one patient developed symptomatic fracture. The distance from the ribs to the tumor site was significantly shorter in fractured ribs than in non-fractured ribs (1.40.3cm vs. 2.5 +/- 0.3cm). Receiver operating characteristic curve analysis showed that D-1cm (3) as a cut-off value for discriminating RIRF had the largest area under the curve (AUC=0.78). Comparison of the two-year cumulative incidence of RIRF among two groups as determined by cut-off values, yielded the following result: 53% vs. 4% [D-1cm (3) >= 38.2 Gy (RBE) or less]. Results from the two groups were significantly different (p<0.05).Conclusion: The crude incidence of RIRF after carbon ion radiotherapy was 39% but incidence of symptomatic fracture was low. The D-1cm (3) as cut-off values may be helpful for discriminating the risk of RIRF.
  • Atsushi Musha, Hirofumi Shimada, Katsuyuki Shirai, Jun-ichi Saitoh, Satoshi Yokoo, Kazuaki Chikamatsu, Tatsuya Ohno, Takashi Nakano
    PLOS ONE 10 (10) e0141734  1932-6203 2015/10 [Refereed][Not invited]
     
    Purpose To evaluate the dose-response relationship for development of acute radiation mucositis (ARM) using an oral mucosal dose surface model (OMDS-model) in carbon ion radiotherapy (C-ion RT) for head and neck tumors. Methods Thirty-nine patients receiving C-ion RT for head and neck cancer were evaluated for ARM (once per week for 6 weeks) according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, and the Radiation Therapy Oncology Group (RTOG) scoring systems. The irradiation schedule typically used was 64 Gy [relative biological effectiveness (RBE)] in 16 fractions for 4 weeks. Maximum point doses in the palate and tongue were compared with ARM in each patient. Results The location of the ARM coincided with the high-dose area in the OMDS-model. There was a clear dose-response relationship between maximum point dose and ARM grade assessed using the RTOG criteria but not the CTCAE. The threshold doses for grade 2-3 ARM in the palate and tongue were 43.0 Gy(RBE) and 54.3 Gy(RBE), respectively. Conclusions The OMDS-model was useful for predicting the location and severity of ARM. Maximum point doses in the model correlated well with grade 2-3 ARM.
  • Takanori Abe, Jun-Ichi Saitoh, Daijiro Kobayashi, Kei Shibuya, Yoshinori Koyama, Hirohumi Shimada, Katsuyuki Shirai, Tatsuya Ohno, Takashi Nakano
    RADIATION ONCOLOGY 10 187  1748-717X 2015/09 [Refereed][Not invited]
     
    Background: The purpose of this study was to compare carbon ion radiotherapy (C-ion RT) and stereotactic radiotherapy (SBRT) with photon beams for the treatment of hepatocellular carcinoma (HCC), specifically with regard to the dose volume parameters for target coverage and normal tissue sparing. Methods: Data of 10 patients who were treated using C-ion RT with a total dose of 60 Gy(RBE) in four fractions were used. The virtual plan of SBRT was simulated on the treatment planning computed tomography images of C-ion RT. Dose volume parameters such as minimum dose covering 90 % of the planning target volume (PTV D90), homogeneity index (HI), conformity index (CI), mean liver dose (MLD), volume of the liver receiving 5 to 60 Gy (V5-60), and max point dose (Dmax) of gastrointestinal (GI) tract were calculated from both treatment plans. Results: The PTV D90 was 59.6 +/- 0.2 Gy(RBE) in C-ion RT, as compared to 56.6 +/- 0.3 Gy in SBRT (p < 0.05). HI and CI were 1.19 +/- 0.03 and 0.79 +/- 0.06, respectively in C-ion RT, as compared to 1.21 +/- 0.01 and 0.37 +/- 0.02, respectively in SBRT. Only CI showed a significant difference between two modalities. Mean liver dose was 8.1 +/- 1.4 Gy(RBE) in C-ion RT, as compared to 16.1 +/- 2.5 Gy in SBRT (p < 0.05). V5 to V50 of liver were higher in SBRT than C-ion RT and significant differences were observed for V5, V10 and V20. Dmax of the GI tract was higher in SBRT than C-ion RT, but did not show a significantly difference. Conclusions: C-ion RT provides an advantage in both target conformity and normal liver sparing compared with SBRT.
  • Oike T, Ohno T, Shirai K, Inoue T, Nakano T
    Clinical case reports 3 (8) 710 - 713 2015/08 [Refereed][Not invited]
  • Noriyuki Okonogi, Katsuyuki Shirai, Takahiro Oike, Kazutoshi Murata, Shin-Ei Noda, Yoshiyuki Suzuki, Takashi Nakano
    ANTICANCER RESEARCH 35 (3) 1229 - 1235 0250-7005 2015/03 [Refereed][Not invited]
     
    Glioblastoma multiforme(GBM) is the most common primary brain tumor in adults, and it is associated with poor survival. The standard therapy for newly-diagnosed GBM is radiotherapy with concurrent temozolomide following maximal surgical resection. To improve the outcome of these patients, combinations of the standard therapy plus molecular-targeted agents have been tested in clinical trials. However, the addition of gefitinib to the standard therapy did not appear to improve clinical outcome, and the standard therapy plus bevacizumab showed no improvement in overall survival, although a 4-month improvement in progression-free survival (PFS) was observed. Phase II data have indicated the potential efficacy of talampanel combined with the standard therapy for patients with newly-diagnosed GBM, and these findings are awaiting validation in phase III trials. In addition, phase II trials have demonstrated that adjuvant immunotherapy is effective and tolerable for treatment of patients with GBM. In this article, we discuss topics in chemotherapy, molecular-targeted therapy, and immunotherapy for patients with newly-diagnosed GBM.
  • Shigehiro Kudo, Yoshiyuki Suzuki, Shin-Ei Nodai, Toshiyuki Mizui, Katsuyuki Shirai, Masahiko Okamoto, Takuya Kaminuma, Yukari Yoshida, Tomoaki Shirao, Takashi Nakano
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 8 (3) 754 - 758 1792-0981 2014/09 [Refereed][Not invited]
     
    Non-proliferating cell, such as mature neurons, are generally believed to be more resistant to X-rays than proliferating cells, such as glial and vascular endothelial cells. Therefore, the late adverse effects of radiotherapy on the brain have been attributed to the radiation-induced damage of glial and vascular endothelial cells. However, little is known about the radiosensitivities of neurons and glial cells due to difficulties in culturing these cells, particularly neurons, independently. In the present study, primary dissociated neurons and glial cultures were prepared separately from the hippocampi and cerebrum, respectively, which had been obtained from the same fetal rat on embryonic day 18. X-irradiations of 50 Gy were performed on the cultured neurons and glial cells at 7 and 21 days in vitro (DIV). The cells were fixed at 24 h after irradiation. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling was then performed to measure the apoptotic indices (AIs). The AIs of non-irradiated and irradiated neurons at 7 DIV were 23.7 +/- 6.7 and 64.9 +/- 4.8%, and those at 21 DIV were 52.1 +/- 17.4 and 44.6 +/- 12.5%, respectively. The AIs of non-irradiated and irradiated glial cells at 7 DIV were 5.8 +/- 1.5 and 78.4 +/- 3.3% and those at 21 DIV were 9.6 +/- 2.6 and 86.3 +/- 4.9%, respectively. Glial cells and neurons were radiosensitive at 7 DIV. However, while glial cells were radiosensitive at 21 DIV, neurons were not.
  • Takeshi Ebara, Hirofumi Shimada, Hidemasa Kawamura, Katsuyuki Shirai, Jun-Ichi Saito, Motohiro Kawashima, Mutsumi Tashiro, Tatsuya Ohno, Tatsuaki Kanai, Takashi Nakano
    ANTICANCER RESEARCH 34 (9) 5099 - 5104 0250-7005 2014/09 [Refereed][Not invited]
     
    Aim: To evaluate dosimetric differences between carbon ion radiotherapy (C-ion RT) and stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC). Patients and Methods: Thirteen stage I NSCLC cases were planned with C-ion RT and SBRT. Prescription of the dose and fractionation (fr) for stage IA and IB in C-ion RT were 52.8 Gy (RBE)/4fr and 60.0 Gy (RBE)/4fr, respectively and those in SBRT were 52.8 Gy/4fr and 60.0 Gy/4fr, respectively. Results: The conformity index (CI) for planning target volume of C-ion RT was significantly lower than that of SBRT. The normal lung doses in C-ion RT were significantly lower those that in SBRT. In particularly, for a larger tumor, C-ion RT was lower CI and normal lung dose than SBRT. Conclusion: C-ion RT has an advantage in both target conformity and sparing of normal lung in stage I NSCLC.
  • Curent Advances in Radiotherapy for Newly Diagnosed Glioblastoma Multiforme.
    Okonogi K, Oike T, Shirai K, tomoaki T, Noda SE, Suzuki Y, Nakano T
    J Neurol Neurophysiol 5 (186) 2014 [Not refereed][Not invited]
  • Kyoichi Kaira, Yoshio Tomizawa, Reiko Yoshino, Akihiro Yoshii, Masana Matsuura, Yasuki Iwasaki, Yasuhiko Koga, Akihiro Ono, Masaki Nishioka, Yosuke Kamide, Takeshi Hisada, Tamotsu Ishizuka, Katsuyuki Shirai, Takeshi Ebara, Jun-ichi Saitoh, Takashi Nakano, Noriaki Sunaga
    LUNG CANCER 82 (3) 449 - 454 0169-5002 2013/12 [Refereed][Not invited]
     
    Purpose: To determine the efficacy and safety of oral S-1 in combination with cisplatin and thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer (NSCLC). Methods and materials: S-1 (50 mg/m(2)) was administered orally twice daily for 14 days, with cisplatin (40 mg/m(2)) on days 1 and 8 of each cycle every 3 weeks, for 2-4 cycles. Thoracic radiation therapy was administered in 2 Gy fractions five times weekly for a total dose of 60 Gy. The primary endpoint was the response rate, and secondary endpoints included progression-free survival, overall survival and safety. Results: Forty-one patients were enrolled in this study. The objective response rate was 87.8% (98% CI: 77.8-97.8%). The median progression-free survival was 467 days (15.4 months), and the median survival time was 904 days (29.7 months). The overall survival rates at 1- and 2-years were 85.7% and 52.9%, respectively. Hematological toxicities included grade 3/4 neutropenia (17%) and grade 3/4 leukopenia (27%). No grade 3 febrile neutropenia was detected, and grade 3/4 non-hematological toxicities were also mild. A grade 3 gastrointestinal hemorrhage was observed in one patient. Conclusions: The combination of oral S-1 plus cisplatin with concurrent radiotherapy is a promising treatment with a high efficacy and lower toxicity in patients with locally advanced NSCLC. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
  • Takahiro Oike, Yoshiyuki Suzuki, Ken-Ichi Sugawara, Katsuyuki Shirai, Shin-Ei Noda, Tomoaki Tamaki, Masaya Nagaishi, Hideaki Yokoo, Yoichi Nakazato, Takashi Nakano
    PLoS ONE 8 (11) e78943  1932-6203 2013/11 [Refereed][Not invited]
     
    This study was conducted to investigate the feasibility and survival benefits of combined treatment with radiotherapy and temozolomide (TMZ), which has been covered by the national health insurance in Japanese patients with glioblastoma since September 2006. Between September 2006 and December 2011, 47 patients with newly diagnosed and histologically confirmed glioblastoma received radiotherapy for 60 Gy in 30 fractions. Among them, 45 patients (TMZ group) received concomitant TMZ (75 mg/m2/day, every day) and adjuvant TMZ (200 mg/m2/day, 5 days during each 28-days). All 36 of the glioblastoma patients receiving radiotherapy between January 1988 and August 2006 were analyzed as historical controls (control group). All patients were followed for at least 1 year or until they died. The median survival was 15.8 months in the TMZ group and 12.0 months in the control group after a median follow-up of 14.0 months. The hazard ratio for death in the TMZ group relative to the control group was 0.52 (P< 0.01) the 2-year survival rate was 27.7% in the TMZ group and 14.6% in the control group. Hematologic toxicity of grade 3 and higher was observed in 20.4% in the TMZ group. Multivariate analysis showed that extent of surgery had the strongest impact on survival (P< 0.01), while the use of TMZ had the second largest impact on survival (P = 0.035). The results indicate that combined treatment with radiotherapy and TMZ has a significant survival benefit for Japanese patients with newly diagnosed glioblastoma with slightly higher toxicities than previously reported. © 2013 Oike et al.
  • Katsuyuki Shirai, Yoshio Tamaki, Yoshizumi Kitamoto, Kazutoshi Murata, Yumi Satoh, Keiko Higuchi, Hitoshi Ishikawa, Tetsuo Nonaka, Takeo Takahashi, Takashi Nakano
    JOURNAL OF RADIATION RESEARCH 54 (4) 706 - 711 0449-3060 2013/07 [Refereed][Not invited]
     
    Esophageal cancer patients are often associated with multiple primary cancers (MPC). The aim of this study is to evaluate the effect of MPC on prognosis in esophageal cancer patients treated by radiotherapy. Between 2001 and 2008, esophageal cancer patients treated by definitive radiotherapy at Gunma Cancer Center were retrospectively reviewed. Exclusion criteria were preoperative or postoperative radiotherapy, palliative radiotherapy, follow-up of < 6 months, radiation dose of < 50 Gy and no information on MPC. We analyzed 167 esophageal cancer patients and 56 (33.5%) were associated with MPC. Gastric cancer was the most frequent tumor (38.2%), followed by head and neck cancer (26.5%). Median follow-up time was 31.5 months (range 6.1-87.3 months). Patients with MPC included more stage I/II esophageal cancer than those without MPC (66.1% vs. 36.9%, P < 0.01). The 5-year overall survival rate for esophageal cancer with MPC was relatively better than those without MPC (46.1% vs. 26.7%), although the difference did not reach statistical significance in univariate analysis (P = 0.09). Stage I/II esophageal cancer patients had a significantly better overall survival than stage III/IV patients (P < 0.01). Among esophageal cancer patients with MPC, there was no difference in overall survival between antecedent and synchronous cancer (P = 0.59). Our study indicated that the prognosis of esophageal cancer patients treated by radiotherapy was primarily determined by the clinical stage itself, but not the presence of MPC.
  • Katsuyuki Shirai, Toshiyuki Mizui, Yoshiyuki Suzuki, Masahiko Okamoto, Kenji Hanamura, Yukari Yoshida, Mizuki Hino, Shin-ei Noda, Wael S. Al-jahdari, Arnab Chakravarti, Tomoaki Shirao, Takashi Nakano
    RADIATION RESEARCH 179 (6) 630 - 636 0033-7587 2013/06 [Refereed][Not invited]
     
    Neurons are essential components of neural circuits and provide brain function organization. We previously reported that X irradiation induces apoptosis in immature neurons. To the best of our knowledge, there have been few reports investigating the effects of X irradiation on mature neurons. We analyzed the effects of X irradiation on the morphology, density and cytoskeletal proteins in dendritic spines on mature neurons. We prepared developing hippocampal neurons from 18 days embryo by using Banker's method. Neurons at 21 days in vitro were X irradiated at several doses and were immediately fixed. To evaluate the dendritic spine morphology and density, the neurons were transfected with a reporter plasmid for enhanced green fluorescent protein (GFP). Changes in the dendritic spines as a result of X irradiation were evaluated using electron microscopy. To analyze the cytoskeletal proteins within the dendritic spines, we performed immunocytochemistry to detect filamentous actin (F-actin), drebrin and PSD-95. X irradiation immediately changed the dendritic spine morphology, and the irradiated spines were significantly thinner and longer than the nonirradiated spines. X irradiation decreased the dendritic spine density in a dose-dependent manner. Electron microscopy confirmed these changes of dendritic spines by X irradiation. Immunohistochemical studies showed that X irradiation decreased the accumulation of drebrin and F-actin, but not PSD-95, within the dendritic spines. These results suggest that X irradiation immediately decreases the dendritic spine density and changes the morphology of mature neurons by reducing the abundance of cytoskeletal proteins. The abnormal dendritic spines may be associated with acute adverse effects after X irradiation in a clinical setting, although further investigations are warranted to validate these findings. (C) 2013 by Radiation Research Society
  • Tomoaki Tamaki, Hitoshi Ishikawa, Takeo Takahashi, Yoshio Tamaki, Yoshizumi Kitamoto, Masahiko Okamoto, Shin-ei Noda, Hiroyuki Katoh, Katsuyuki Shirai, Hideyuki Sakurai, Takashi Nakano
    BRACHYTHERAPY 11 (2) 130 - 136 1538-4721 2012/03 [Refereed][Not invited]
     
    PURPOSE: To compare the efficacy and the incidence of complications of high-dose-rate (HDR) and low-dose-rate (LDR) intraluminal brachytherapy (IBT) boost after external beam radiation therapy in patients with superficial esophageal cancer. METHODS AND MATERIALS: Fifty-four consecutive patients with Stage I thoracic esophageal squamous cell carcinoma who were treated with definitive radiotherapy using 1BT between 1991 and 2007 were studied retrospectively. LDR-IBT and HDR-IBT were performed for 19 and 35 patients, respectively. After external beam radiation therapy of 56-60 Gy with a conventional fractionation, LDR-IBT (5 Gy x 2) or HDR-IBT (3 Gy x 3) was given within 2 weeks. The median follow-up was 47 months (7-151 months). RESULTS: Overall, the 5-year overall survival, cause-specific survival (CSS), and locoregional control (LRC) rates were 61%, 86%, and 79%, respectively. The 5-year overall survival, CCS, and LRC rates did not differ significantly between the LDR-IBT and HDR-IBT groups (68% vs. 58% (p = 0.50), 83% vs. 85% (p = 0.63), and 84% vs. 75% (p = 0.42), respectively). Salvage treatment was given in 8 locally recurrent patients, and 6 patients were rescued. The Grade >= 2 late morbidities of esophagus and heart/lung were observed in 5 patients (4 in the LDR-IBT group and 1 in the HDR-IBT group) and 2 patients (one from each group), respectively. CONCLUSIONS: In view of the safety profile and effectiveness, our results encourage the continued adoption of HDR-IBT as radiation boost in medically inoperable or elderly superficial esophageal cancer patients undergoing definitive radiotherapy. (C) 2012 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
  • Shirai K, Siedow MR, Chakravarti A
    Journal of oncology 2012 193436  1687-8450 2012 [Refereed][Not invited]
  • Yukari Yoshida, Yoshiyuki Suzuki, Wael S. Al-Jahdari, Nobuyuki Hamada, Tomoo Funayama, Katsuyuki Shirai, Hiroyuki Katoh, Tetsuya Sakashita, Yasuhiko Kobayashi, Takashi Nakano
    JOURNAL OF RADIATION RESEARCH 53 (1) 87 - 92 0449-3060 2012/01 [Refereed][Not invited]
     
    To clarify the relative biological effectiveness (RBE) values of carbon ion (C) beams in normal brain tissues, a rat organotypic slice culture system was used. The cerebellum was dissected from 10-day-old Wistar rats, cut parasagittally into approximately 600-mu m-thick slices and cultivated using a membrane-based culture system with a liquid-air interface. Slices were irradiated with 140 kV X-rays and 18.3 MeV/amu C-beams (linear energy transfer = 108 keV/mu m). After irradiation, the slices were evaluated histopathologically using hematoxylin and eosin staining, and apoptosis was quantified using the TdT-mediated dUTP-biotin nick-end labeling (TUNEL) assay. Disorganization of the external granule cell layer (EGL) and apoptosis of the external granule cells (EGCs) were induced within 24 h after exposure to doses of more than 5 Gy from C-beams and X-rays. In the early postnatal cerebellum, morphological changes following exposure to C-beams were similar to those following exposure to X-rays. The RBEs values of C-beams using the EGL disorganization and the EGC TUNEL index endpoints ranged from 1.4 to 1.5. This system represents a useful model for assaying the biological effects of radiation on the brain, especially physiological and time-dependent phenomena.
  • Naduparambil K. Jacob, James V. Cooley, Katsuyuki Shirai, Arnab Chakravarti
    ONCOTARGETS AND THERAPY 5 7 - 20 1178-6930 2012 [Refereed][Not invited]
     
    Survivin is a critical regulator of mitosis, and an inhibitor of apoptosis which is overexpressed in almost all cancers. In the current study, cell cycle profiles of normal proliferating human umbilical vein endothelial cells, prostate cancer, and lung cancer cell lines expressing varying levels of survivin and its splice variants were compared using a novel functional complementation assay. Defects in chromosome segregation and cytokinesis that were observed after depletion of endogenous survivin were not complemented by any of the survivin splice variants: survivin-2B, survivin-3B, survivin-Ex3, or survivin-2A when expressed exogenously at a level comparable to endogenous full-length survivin. Survivin variants were not detectable at the endogenous protein level. Cancer cells with higher levels of full-length survivin and survivin-2B expression, exhibited reduced caspase-3 activation following doxorubicin treatment and radiation. Whereas earlier studies focused on function and expression levels of survivin specific to cancer cells, the current study brings forward the essential role of survivin in normal dividing cells. Full-length survivin was found to be associated with Aurora-B kinase in the chromosomal passenger complex and depletion of survivin mimics mitotic phenotypes observed after Aurora-B kinase inhibition, in cancer as well as normal proliferating cells. Thus, our study establishes survivin as a marker of proliferation, rather than a cancer specific marker. Therefore, systemic therapeutic interventions targeting survivin will affect cancer as well as normal proliferating cells.
  • Perry J, Okamoto M, Guiou M, Shirai K, Errett A, Chakravarti A
    Neurology research international 2012 428565  2090-1852 2012 [Refereed][Not invited]
  • Shirai K, Nakagawa A, Abe T, Kawahara M, Saitoh J, Ohno T, Nakano T
    International journal of molecular imaging 2012 609545  2090-1712 2012 [Refereed][Not invited]
  • Takahiro Oike, Yoshiyuki Suzuki, Wael Al-Jahdari, Abdulelah Mobaraki, Jun-Ichi Saitoh, Kohta Torikai, Katsuyuki Shirai, Takashi Nakano
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 3 (1) 141 - 145 1792-0981 2012/01 [Refereed][Not invited]
     
    Recently, it has become clear that acute hypoxia affecting radioresistance exists widely in tumor tissues. Concurrently, hypoxia-inducible factor-1 alpha (HIF-1 alpha) is recognized as an essential transcriptional factor, enabling cells to survive through hypoxia. However, it is unclear as to whether HIF-1 alpha plays a direct role in the radioresistance caused by acute hypoxia. Therefore, in this study, we investigated the in vitro response of the human lung adenocarcinoma cell line, A549, to ionizing radiation in an experimental model that imitates acute hypoxia in the presence and absence of HIF-1 alpha expression, using the HIF-1 alpha inhibitor 5-[1-(phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol (YC-1). Cells were treated with or without 10 mu M YC-1 for 2 h. Cells were exposed to either 95% N-2 and 5% CO2 (hypoxic condition of <0.1 mmHg) or atmospheric air (normoxic condition) for 1 h, and irradiated with 2, 5 and 10 Gy. Western blot analysis revealed that, without YC-1, cells exposed to hypoxic conditions expressed increased levels of HIF-1 alpha compared with those exposed to normoxic conditions. Under hypoxic conditions, HIF-1 alpha expression was suppressed by YC-1 to the same extent as that observed in cells exposed to normoxic conditions without YC-1. Clonogenic survival assay revealed that under hypoxic conditions there was no significant difference between the surviving fraction of cells treated with YC-1 and without YC-1 at any dose point examined. The oxygen enhancement ratio at 10% surviving fraction was calculated as 2.7 and 2.6 in the presence and the absence of YC-1, respectively. These results indicate that HIF-1 alpha itself is not an immediate cause of acute hypoxia-induced radioresistance in A549 cells.
  • Katsuyuki Shirai, Arnab Chakravarti
    EXPERT REVIEW OF ANTICANCER THERAPY 11 (12) 1935 - 1944 1473-7140 2011/12 [Refereed][Not invited]
     
    Combined therapy with temozolomide and radiotherapy is a standard treatment and improves the survival for patients with newly diagnosed glioblastoma. However, the prognosis remains poor, with a median survival time of 12-15 months. Currently, several clinical trials of dose-dense temozolomide regimen or molecular-targeting therapies have been performed to overcome the resistance of glioblastoma. In these therapies, rational prognostic biomarkers have also been investigated to predict their outcome and response to treatment. This advanced understanding of the biological markers can help to develop personalized therapies for glioblastoma patients. Generally, due to a reduced tolerance, elderly patients do not seem to benefit from intensive treatment. This population needs individual treatments depended on their age or performance status. In this article, we review the recent studies that can provide personalized therapy for glioblastoma, based on molecular tumor profiling or patients' physical status.
  • Mersiha Hadziahmetovic, Katsuyuki Shirai, Arnab Chakravarti
    FUTURE ONCOLOGY 7 (10) 1169 - 1183 1479-6694 2011/10 [Refereed][Not invited]
     
    Gliomas account for the vast majority of malignant adult brain tumors. Even though tremendous effort has been made to optimize treatment of patients with high-grade glioma, the prognosis remains poor, especially for patients with glioblastoma. The dismal prognosis conferred by these tumors is in part caused by the tendency to diffusely infiltrate into neighboring brain tissue, but also by the inherent resistance of these tumors to both chemotherapy and radiation. This article reviews the recent advancements in multimodality treatment of patients with gliomas, both in the primary and recurrent setting, with an emphasis on the emerging targeted therapies. Moreover, the external beam radiotherapy options, including intensity modulated radiotherapy and particle (proton and carbon ion) radiotherapy are reviewed.
  • Katsuyuki Shirai, Yoshio Tamaki, Yoshizumi Kitamoto, Kazutoshi Murata, Yumi Satoh, Keiko Higuchi, Tetsuo Nonaka, Hitoshi Ishikawa, Hiroyuki Katoh, Takeo Takahashi, Takashi Nakano
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 80 (4) 1002 - 1007 0360-3016 2011/07 [Refereed][Not invited]
     
    Purpose: To investigate the dose volume histogram parameters and clinical factors as predictors of pleural effusion in esophageal cancer patients treated with concurrent chemoradiotherapy (CRT). Methods and Materials: Forty-three esophageal cancer patients treated with definitive CRT from January 2001 to March 2007 were reviewed retrospectively on the basis of the following criteria: pathologically confirmed esophageal cancer, available computed tomography scan for treatment planning, 6-month follow-up after CRT, and radiation dose >= 50 Gy. Exclusion criteria were lung metastasis, malignant pleural effusion, and surgery. Mean heart dose, mean total lung dose, and percentages of heart or total lung volume receiving >= 10-60 Gy (Heart-V-10 to V-60 and Lung-V-10 to V-60, respectively) were analyzed in relation to pleural effusion. Results: The median follow-up time was 26.9 months (range, 6.7-70.2) after CRT. Of the 43 patients, 15(35%) developed pleural effusion. By univariate analysis, mean heart dose, Heart-V-10 to V-60, and Lung-V-50 to V-60 were significantly associated with pleural effusion. Poor performance status, primary tumor of the distal esophagus, and age years were significantly related with pleural effusion. Multivariate analysis identified Heart-V-50 as the strongest predictive factor for pleural effusion (p = 0.01). Patients with Heart-V-50 <20%, 20% Heart-V-50 <40%, and Heart-V5(0_) >= 40% had 6%, 44%, and 64% of pleural effusion, respectively (p < 0.01). Conclusion: Heart-V-50 is a useful parameter for assessing the risk of pleural effusion and should be reduced to avoid pleural effusion. (C) 2011 Elsevier Inc.
  • Katsuyuki Shirai, Yoshio Tamaki, Yoshizumi Kitamoto, Takeo Takahashi, Hitoshi Ishikawa, Tetsuo Nonaka, Kazutoshi Murata, Yumi Satoh, Keiko Higuchi, Takashi Nakano
    JOURNAL OF RADIATION RESEARCH 52 (3) 264 - 269 0449-3060 2011/05 [Refereed][Not invited]
     
    Despite the wide use of definitive chemoradiotherapy (CRT) for locally advanced esophageal adenocarcinoma, there is little evidence that CRT improves the survival of patients with esophageal adenocarcinoma compared with radiotherapy (RT) alone. Therefore, we retrospectively evaluated the outcome of patients with esophageal adenocarcinoma treated by CRT and RT alone. Patients were treated at the Gunma Prefectural Cancer Center (Ota, Japan) and the Gunma University Hospital (Maebashi, Japan). Patients provided written informed consent before treatment. Patients with distant metastases were excluded. CRT consisting of RT, nedaplatin, and 5-fluorouracil has been performed since 2002 when patients have adequate bone marrow, liver, and renal function. Between November 1993 and April 2006, 8 patients were treated by CRT and 12 were RT alone. The median follow-up period of surviving patients was 19 months. CRT group had a significantly higher complete response rate than those RT alone group (87% vs. 33%, P = 0.05). Of all patients, 2-year overall survival rate was 41% and the median survival time was 18 months. The 2-year overall survival of patients treated by CRT was 58%, significantly better than 24% of those with RT alone (P = 0.02). CRT can improve outcomes of patients with esophageal adenocarcinoma compared with RT alone.
  • Takuya Kaminuma, Yoshiyuki Suzuki, Katsuyuki Shirai, Toshiyuki Mizui, Shin-ei Noda, Yukari Yoshida, Tomoo Funayama, Takeo Takahashi, Yasuhiko Kobayashi, Tomoaki Shirao, Takashi Nakano
    JOURNAL OF RADIATION RESEARCH 51 (6) 627 - 631 0449-3060 2010/11 [Refereed][Not invited]
     
    The direct biological effects of radiation, particularly accelerated heavy particle ions, on neurons are not fully known. Hence, the direct effect of carbon-ion beams on immature neurons was investigated by comparing to the effect of X-rays in vitro using primary hippocampal neurons. Primary neurons were prepared from hippocampi of fetal rats at embryonic day 18 from timed pregnant Wistar rats and cultured with Banker's methods. At 7 Days In Vitro (DIV), the cells were irradiated with 140 kV X-ray and 18.3 MeV/amu carbon-ion beams (LET = 108 keV/mu m). The cells were fixed with 4% paraformaldehyde at 12 hours after irradiation. Then, the cells were treated with terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and DAPI staining for measuring the percentage of apoptosis (apoptotic index: Al). Al in sham-irradiated hippocampal neurons was 18%. The value of Al (Als) of the cells irradiated with X-rays at 10 or 30 Gy were 15% or 23%, respectively. Al in cells irradiated with carbon-ion beams at 1 Gy, 3 Gy, 5 Gy and 10 Gy were 22%, 23%, 24% and 33%, respectively. Al was significantly increased by carbon-ion beams at 10 Gy (p < 0.001). The apoptosis of hippocampal neurons increased in a dose-dependent manner following both X-ray and carbon-ion beams irradiation. Carbon-ion beams were about 10-fold more effective than X-rays for apoptosis induction in immature hippocampal neurons.
  • Katsuyuki Shirai, Yoshiyuki Suzuki, Masahiko Okamoto, Masaru Wakatsuki, Shin-Ei Noda, Takeo Takahashi, Shogo Ishiuchi, Masatoshi Hasegawa, Yoichi Nakazato, Takashi Nakano
    JOURNAL OF RADIATION RESEARCH 51 (5) 589 - 594 0449-3060 2010/09 [Refereed][Not invited]
     
    World Health Organization (WHO) grade 3 glioma is one of the common brain tumors and has three main histological subtypes, including anaplastic astrocytoma (AA), anaplastic oligoastrocytoma (AOA) and anaplastic oligodendroglioma (AO). However, most previous studies have considered AOA and AO as one group because of the difficult differential diagnosis between AOA and AO. Therefore the prognostic difference among patients with these histological subtypes has been unclear. In this study, 68 patients with histologically proven WHO grade 3 glioma, consecutively received postoperative radiotherapy at the Gunma University Hospital, Japan, between 1983 and 2005, were investigated to assess the impact of histological subtype on the survival. The number of AA, AOA and AO patients was 41, 16 and 11, respectively. The mean and median follow-up periods were 72 and 48 months, respectively. The number of patients treated with gross total resection, partial resection and biopsy was 14, 38 and 16, respectively. The mean and median radiation doses were 58 +/- 5 Gy and 60 Gy, respectively. The 5-year overall survival rates of AA, AOA and AO were 21%, 38% and 80%, and median survival period were 16 months, 58 months and not reached, respectively. Univariate analysis showed that the histological subtype (P < 0.01) and extent of surgery (P < 0.01) were significant prognostic factors for survival. Selective comparison showed that overall survival of patients with AA was significantly worse than for those with AOA (P = 0.01) and AO (P < 0.01). The overall survival of patients with AO was better than for those with AOA; however, the difference was not statistically significant (P = 0.14). Multivariate analysis demonstrated that histological subtype, age and extent of surgery were the significant independent variable for survival (P < 0.01, P <0.01 and P = 0.04). In our study, histological subtype was one of the most important prognostic factors of WHO grade 3 glioma.
  • Yoshiyuki Suzuki, Katsuyuki Shirai, Kuniyuki Oka, Abdulelah Mobaraki, Yukari Yoshida, Shin-ei Noda, Masahiko Okamoto, Yoshihiko Suzuki, Jun Itoh, Hideaki Itoh, Shogo Ishiuchi, Takashi Nakano
    JOURNAL OF RADIATION RESEARCH 51 (3) 343 - 348 0449-3060 2010/05 [Refereed][Not invited]
     
    phosphorylated-Akt (pAkt) plays an important role in tumorigenesis through promotion of cell survival by inhibiting apoptosis and mediating cell proliferation Higher expression of pAkt has been reported to be associated with an unfavorable prognosis in several malignant tumors In this study, the prognostic value of pAkt expression was investigated in glioblastomas by using immunohistochemical methods Tissue sections obtained from 64 patients with glioblastoma were evaluated The mean and median follow-up period was 16 2 +/- 12 4 and 12 months. respectively (range. from 1 to 62 months) pAkt expression levels were determined by immunohistochemical staining and evaluated for cell positivity Positive staining was defined when more than 50% of the tumor cells were stained in each section The correlation between expression of pAkt and overall survival rate was assessed. Glioblastomas showed either or both cytoplasmic and nuclear positive findings for pAkt A total of 29 7% (19/64) of tissue specimens had greater than 50% positivity The median survival periods of the patients with pAkt positive and negative tumor were 10 and 14 months. respectively Two years overall survival rate of the pAkt positive and negative patients were 0% and 24 4%. respectively Survival rate of the patients with pAkt positive tumor was significantly lower than that of the patients with pAkt negative tumors (p = 0 004) Multivariate analysis showed that extent of surgery was the strongest factor for survival (p = 0 01) and the pAkt expression was the secondly strongest factor (p = 0.06) These results suggest that the higher expression of pAkt the poorer prognosis in patients with glioblastoma
  • Hitoshi Ishikawa, Tetsuo Nonaka, Hideyuki Sakurai, Yoshio Tamaki, Yoshizumi Kitamoto, Takeshi Ebara, Mariko Shioya, Shin-Ei Noda, Katsuyuki Shirai, Yoshiyuki Suzuki, Takeo Takahashi, Takashi Nakano
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 76 (2) 452 - 459 0360-3016 2010/02 [Refereed][Not invited]
     
    Purpose: To assess the efficacy of radiation therapy (RT) by using intraluminal brachytherapy (IBT) combined with external beam RT (EBRT) for submucosal esophageal cancer. Methods and Materials: Between 1991 and 2005,59 consecutive patients received definitive RT without chemotherapy. IBT was performed after patients completed EBRT as a booster therapy for 17 patients, using low-dose-rate Cs-137 sources until 1997, and for 19 patients, using high-dose-rate Ir-192 sources thereafter. The long-term outcomes were investigated with a median follow-up time of 61 months. Results: Logoregional recurrences and distant metastases were observed in 14 patients and in 2 patients in the lung, respectively, and 5 patients were rescued by salvage treatments. The 5-year logoregional control and cause-specific survival rates were 75% and 76%, respectively. The 5-year cause-specific survival rate in the EBRT group was 62%, whereas the corresponding rate in the IBT group was 86% (p=0.04). Multivariate analysis revealed that IBT was the most powerful predictor of survival but did not reach a significant level (p=0.07). There were five esophageal ulcers in the IBT group, but no ulcers developed with small fractions of 3 Gy. Grade 2 or higher cardiorespiratory complications developed in 2 patients (5.6%) in the IBT group and in 3 patients (13.0%) in the EBRT group. Conclusions: Combining IBT with EBRT is suggested to be one of the preferable treatment modalities for medically inoperable submucosal esophageal cancer because of its preferable local control and survival probabilities, with appreciably less morbidity. (C) 2010 Elsevier Inc.
  • Masahiko Okamoto, Yoshiyuki Suzuki, Katsuyuki Shirai, Toshiyuki Mizui, Yukari Yoshida, Shin-ei Noda, Wael S. Al-Jahdari, Tomoaki Shirao, Takashi Nakano
    RADIATION RESEARCH 172 (6) 718 - 724 0033-7587 2009/12 [Refereed][Not invited]
     
    Okamoto, M., Suzuki, Y., Shirai, K., Mizui, T., Yoshida, Y., Noda, S., Al-Jahdari, W. S., Shirao, T. and Nakano, T. Effect of Radiation on the Development of Immature Hippocampal Neurons In Vitro. Radiat. Res. 172, 718-724 (2009). Little is known about the direct biological effects of radiation on immature neurons, despite its relevance to the mental retardation caused by irradiation of the brains of fetuses and children. In this study, we investigated the effects of radiation using primary cultured hippocampal neuronal cells with exclusion of glial cells, focusing on cell survival and structural development. Primary neurons were prepared from the hippocampi of fetal rats at embryonic day 18 and cultured according to Banker's methods. After incubation for 7 days, cells were irradiated with X rays and incubated continuously for 7 or 14 days. The number of neurons, their rate of apoptosis, and the patterns of expression of synaptic proteins on the neural dendrites were investigated by immunohistochemical methods. The total numbers of neurons were the same regardless of whether they were irradiated. The number of TUNEL-positive neurons, which can be considered as undergoing apoptosis, increased significantly in a dose-dependent fashion at both 7 and 14 days after irradiation. The mean numbers of clusters of synaptic proteins on neural dendrites, which are considered to represent their developmental level, decreased dose-dependently at both 7 and 14 days after irradiation. These results suggest that radiation not only induces apoptosis but also produces structural defects in the surviving neurons that may directly suppress neural development. (C) 2009 by Radiation Research Society
  • Katsuyuki Shirai, Yoshiyuki Suzuki, Kuniyuki Oka, Shin-ei Noda, Hiroyuki Katoh, Yoshihiko Suzuki, Jun Itoh, Hideaki Itoh, Shogo Ishiuchi, Hideyuki Sakurai, Masatoshi Hasegawa, Takashi Nakano
    JOURNAL OF NEURO-ONCOLOGY 91 (3) 353 - 358 0167-594X 2009/02 [Refereed][Not invited]
     
    Survivin is a member of the inhibitor of apoptosis family, and is expressed in various malignant tumors. Survivin overexpression has been reported to be a poorer prognostic factor in various malignancies. However, the prognostic value of survivin expression in patients with glioblastoma is still controversial. Therefore, in this study the role of survivin as a predictor for survival was investigated in patients with glioblastoma. Tissue specimens were obtained from 66 patients with glioblastoma treated with radiotherapy. Survivin expression was detected by an immunohistochemical method. Nuclear and cytoplasm survivin scores were defined by using the cell positivity and staining intensity. The scores were defined as follows, 0 (no staining), 1 (less than 50% of cell positivity and any staining), 2 (more than 50% of cell positivity and weak to moderate intensity) and 3 (more than 50% of cell positivity and strong intensity). The correlation between survivin scores and the overall survival rate was evaluated. Nuclear and cytoplasm survivin staining were noted in 47 and 58 patients, respectively. The number of patients with nuclear survivin score of 0, 1, 2 and 3, were 19 (28.8%), 26 (39.4%), 9 (13.6%) and 12 (18.2%), respectively. The 3-year overall survival rate of the nuclear survivin score 3 was 0%, significantly lower than the 11.6% of the nuclear survivin score a parts per thousand currency sign2 (P = 0.0003). Cytoplasm survivin score did not correlate with the prognosis. Nuclear survivin expression may be a useful biomarker for predicting prognosis in patients with glioblastoma.
  • Wael S. Al-Jahdari, Yoshiyuki Suzuki, Yukari Yoshida, Nobuyuki Hamada, Katsuyuki Shirai, Shin-Ei Noda, Tomoo Funayama, Tetsuya Sakashita, Yasuhiko Kobayashi, Shigeru Saito, Fumio Goto, Takashi Nakano
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY 85 (8) 700 - 709 0955-3002 2009 [Refereed][Not invited]
     
    Purpose: Recently carbon-ion beams have been reported to be remarkably effective for controlling various cancers with less toxicity and are thought to be a promising modality for cancer treatment. However, the biological effect of carbon-ion beams arising on normal neuron remains unknown. Therefore, this study was undertaken to investigate the effect of carbon-ion beams on neurons by using both morphological and functional assays. Materials and methods: Dorsal root ganglia (DRG) and sympathetic ganglion chains (SYMP) were isolated from day-8 and day-16 chick embryos and cultured for 20h. Cultured neurons were exposed to carbon-ion beams and X-rays. Morphological changes, apoptosis and cell viability were evaluated with the Growth Cone Collapse (GCC), Terminal deoxynucleotidyl Transferase (TdT)-mediated deoxyUridine TriPhosphate (dUTP) nick End Labeling [TUNEL] assay and 4-[3-(4-iodophenyl)- 2-(4-nitrophenyl)- 2H-5-tetrazolio]- 1,3-benzenedisulfonate [WST-1] assays, respectively. Results: Irradiation caused GCC and neurite destruction on a time- and irradiation dose-dependent manner. Changes in morphological characteristics were similar following either irradiation. Morphological and functional assays showed that day-8 neurons were more radiosensitive than day-16 neurons, whereas, radiosensitivity of DRG was comparable to that of SYMP. The dose-response fitting curve utilising both GCC and TUNEL labeling index showed higher relative biological effectiveness (RBE) values were associated with lower lethal dose (LD) values, while lower RBE was associated with higher LD values. Conclusion: Exposure to high-linear energy transfer (LET) irradiation is up to 3.2 more efficient to induce GCC and apoptosis, in early developed neuronal cells, than low-LET irradiation. GCC is a reliable method to assess the radiobiological response of neurons.
  • Wael S. Al-Jahdari, Yoshiyuki Suzuki, Yukari Yoshida, Shin-ei Nodai, Katsuyuki Shirai, Shigeru Saito, Fumio Goto, Takashi Nakano
    JOURNAL OF RADIATION RESEARCH 49 (5) 481 - 489 0449-3060 2008/09 [Refereed][Not invited]
     
    The growth cone is a structure at the terminal of a neurite that plays an important role in the growth of the neurite. The growth cone collapse assay is considered to be a useful method to quantify the effects of various factors on nerve tissue. Here, we investigated the effect of x-irradiation on growth cones and neurites and also the comparative radiosensitivity of different neurons. Dorsal root ganglia and sympathetic chain ganglion were isolated from day-8 and -16 chick embryos and cultured for 20 h. Neurons were then exposed to x-irradiation and morphological changes were quantitatively evaluated by growth cone collapse assay. Cell viability was examined using TUNEL and WST-1 assays. The results showed that radiation induced growth cone collapse and neurite retraction in a time- and exposure-responsive manner. Growth cone collapse, apoptosis and WST-1 assays showed that no significant difference between the neurons throughout the study period (p >= 0.5) after irradiation. Both types of day-8 neurons were more radiosensitive than day-16 neurons (p <= 0.05). The time course of the growth cone collapse was significantly correlated with the apoptotic and cell viability responses at different irradiation doses. Growth cone collapse may represent a useful marker for assaying the effect of x-irradiation on normal cell neurons.
  • Fukamoto K, Shirai K, Sakata T, Sakashita T, Funayama T, Hamada N, Wada S, Kakizaki T, Shimura S, Kobayashi Y, Kiguchi K
    Journal of radiation research 48 (3) 247 - 253 0449-3060 2007/05 [Refereed][Not invited]
  • Masaru Wakatsuki, Yoshihiko Suzuki, Soken Nakamoto, Tatsuya Ohno, Hitoshi Ishikawa, Hiroki Kiyohara, Makoto Kiyozuka, Katsuyuki Shirai, Yuko Nakayama, Takashi Nakano
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 22 (5) 715 - 719 0815-9319 2007/05 [Refereed][Not invited]
     
    Aim: The aim of this study was to examine the clinical usefulness of cytokeratin 19 fragments (CYFRA 21-1) compared with squamous cell carcinoma (SCC) antigen in patients with esophageal cancer treated with radiation therapy. Methods: Fifty-one patients with stage I-IV esophageal cancer were evaluated. CYFRA 21-1 and SCC antigen serum levels were measured at the start and the end of radiation therapy. Results: CYFRA 21-1 (> 3.5 ng/mL) and SCC antigen (> 1.5 ng/mL) before radiation therapy were elevated in 63% and 53% of the patients, respectively. The CYFRA 21-1 levels were significantly correlated with TNM stages, tumor depth and lymph node metastasis (P = 0.0003, P = 0.019 and P = 0.019, respectively), whereas no correlation was observed between SCC antigen and these factors. The values of CYFRA 21-1 in all patients who survived without recurrence were under the cutoff level at the end of treatment, but the values in all patients with locoregional recurrence were above the level. However, there was no significant correlation between SCC antigen level at the end of treatment and any clinical outcome. Conclusions: The results suggest that the evaluation of CYFRA 21-1 would be useful not only for assessment before radiation therapy but also for monitoring after radiation therapy in the treatment for esophageal cancer.
  • Yoshiyuki Suzuki, Kuniyuki Oka, Daisaku Yoshida, Katsuyuki Shirai, Tatsuya Ohno, Shingo Kato, Hirohiko Tsujii, Takashi Nakano
    GYNECOLOGIC ONCOLOGY 104 (3) 642 - 646 0090-8258 2007/03 [Refereed][Not invited]
     
    Objective. Survivin is a member of the inhibitors of apoptosis and has been implicated in both the regulation of cell division and the suppression of apoptosis. Over-expression of cytoplasmic survivin correlates with an unfavorable prognosis in many malignant tumors. However, the prognostic value of nuclear survivin expression is still equivocal. Here, we investigated the prognostic value of survivin expression in cervical cancer treated with radiation therapy. Methods. Tissue sections were obtained from 72 patients with cervical squamous cell carcinoma treated with radiation therapy alone. Survivin expression levels were determined by imintmohistochemical staining and evaluated for cell positivity. The correlation between survivin expression and clinical outcome endpoints including cause-specific survival and local control were evaluated. Results. A total of 14% (10/72) of tissue specimens had greater than 5% nucleus positivity, while 47% (34/72) had greater than 50% cytoplasmic positivity. Local control rate of the cytoplasmic survivin-negative tumors was 94%, significantly higher than the 76% of the positive tumors (p=0.046). Local control rate of the nuclear survivin-positive and cytoplasmic survivin-negative patients was 95%, significantly higher than the 74% of the other patients (p=0.02). In contrast, no significant correlation was noted between survivin expression and disease-free survival. Conclusions. The cytoplasmic survivin expression alone and the combination of nuclear and cytoplasmic expression were suggested to be predictors for local control in patients with cervical squamous cell carcinoma treated with radiation therapy alone. (c) 2006 Elsevier Inc. All rights reserved.
  • Takeshi EBARA, Tetsuo AKIMOTO, Hiroyuki KATO, Shin-ei NODA, Tomoaki TAMAKI, Kosaku HARADA, Katsuyuki SHIRAI, Hidemasa KAWAMURA, Hideyuki SAKURAI, Takashi NAKANO
    The Official Journal of The Japanese Society for Therapeutic Radiology and Oncology 19 93 - 97 2007 [Not refereed][Not invited]
  • Hitoshi Ishikawa, Yuko Nakayama, Yoshizumi Kitamoto, Tetsuo Nonaka, Hidemasa Kawamura, Katsuyuki Shirai, Hideyuki Sakurai, Kazushige Hayakawa, Hideo Niibe, Takashi Nakano
    LUNG 184 (6) 347 - 353 0341-2040 2006/12 [Refereed][Not invited]
     
    Japanese randomized trials showed that there was a significant impact on survival from stage I adenocarcinoma (AD) of the lung by adjuvant chemotherapy with uracil-tegaful after complete resection but there was no effect for patients with squamous cell carcinoma (SQ). The purpose of this study was to examine the correlation of tumor histology and clinical outcome of radiation therapy (RT) for stage I non-small-cell lung cancer (NSCLC) and to consider the necessity of adjuvant chemotherapy after RT for these patients. The subjects were 83 patients, 54 with SQ and 29 with AD; they had received definitive RT with the total dose ranging from 60 to 80 Gy with conventional fractionation at a daily dose of 2 Gy. The differences between SQ and AD with respect to survival and recurrence pattern were investigated. The 5-year overall survival and cause-specific survival rates were 26.5% and 49.1%, respectively. No difference in survival was observed between SQ and AD patients, and the recurrence rates were almost identical (44% for SQ and 45% for AD). However, the 5-year primary control rate of SQ was significantly poorer than that of AD (SQ: 61.5%; AD: 87.6%; p = 0.03). Conversely, the 5-year metastasis-free survival rate of SQ was significantly better than that of AD (SQ: 88.2%; AD: 53.0%; p = 0.005). The different failure pattern, according to tumor histology, indicates that taking into consideration the difference in their clinical behaviors would also be important for planning RT and surgery for early lung cancer.
  • T Akimoto, H Katoh, Y Kitamoto, T Tamaki, K Harada, K Shirai, T Nakano
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 65 (2) 364 - 370 0360-3016 2006/06 [Refereed][Not invited]
     
    Purpose: To evaluate the incidence of Grade 2 or worse rectal bleeding after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiotherapy (EBRT), with special emphasis on the relationship between the incidence of rectal bleeding and the rectal dose from HDR brachytherapy. Methods and Materials: The records of 100 patients who were treated by HDR brachytherapy combined with EBRT for >= 12 months were analyzed. The fractionation schema for HDR brachytherapy was prospectively changed, and the total radiation dose for EBRT was fixed at 51 Gy. The distribution of the fractionation schema used in the patients was as follows: 5 Gy X 5 in 13 patients; 7 Gy X 3 in 19 patients; and 9 Gy X 2 in 68 patients. Results: Ten patients (10%) developed Grade 2 or worse rectal bleeding. Regarding the correlation with dosimetric factors, no significant differences were found in the average percentage of the entire rectal volume receiving 30%, 50%, 80%, and 90% of the prescribed radiation dose from EBRT between those with bleeding and those without. The average percentage of the entire rectal volume receiving 10%, 30%, 50%, 80%, and 90% of the prescribed radiation dose from HDR brachytherapy in those who developed rectal bleeding was 77.9%, 28.6%, 9.0%, 1.5%, and 0.3%, respectively, and was 69.2%, 22.2%, 6.6%, 0.9%, and 0.4%, respectively, in those without bleeding. The differences in the percentages of the entire rectal volume receiving 10%, 30%, and 50% between those with and without bleeding were statistically significant. Conclusions: The rectal dose from HDR brachytherapy for patients with prostate cancer may have a significant impact on the incidence of Grade 2 or worse rectal bleeding. (c) 2006 Elsevier Inc.
  • K Shirai, T Mizui, Y Suzuki, Y Kobayashi, T Nakano, T Shirao
    NEUROSCIENCE LETTERS 399 (1-2) 57 - 60 0304-3940 2006/05 [Refereed][Not invited]
     
    X-irradiation to neuronal progenitor cells causes brain dysfunctions, such as a mental retardation, in adulthood. However, little has been known about the degree of radiosensitivity of neurons in the developmental stages at which they are most vulnerable. In this study we compared the effect of irradiation on mature neurons with that on immature neurons. Primary dissociated neuronal cultures were prepared from fetal rat hippocampi of embryonic day 18. X-irradiations were performed on the cultured cells at 7 or 21 days in vitro (DIV), and the cells were fixed at 12 or 24 h after irradiation. Then the cells were stained with 4',6-diamidino-2-phenylindole (DAPI) or terminal deoxynucleotidyl transferase- mediated dUTP nick end labeling (TUNEL). The apoptotic changes were measured quantitatively by nuclear pyknosis and DNA fragmentation-both characteristic morphological changes of apoptosis. Light microscopy with differential interference contrast showed that 30 Gy of irradiation increased cellular shrinkage in 7-DIV neurons but not in 21 -DIV neurons. Quantitative analysis using DAPI imaging showed that 30 Gy of irradiation significantly enhanced pyknotic changes in 7-DIV neurons after 24 h. In contrast, this irradiation did not enhance any pyknotic changes in 21 -DIV neurons after 24 h. Further TUNEL staining also showed that the irradiation did not enhance any DNA fragmentation in nuclei of 21-DIV neurons after 24 h. Hence, we showed that the radiosensitivity of 21 -DIV postmitotic neurons was significantly lower than that of 7-DIV neurons, indicating that the susceptibility of such neurons depends on their developmental stage. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
  • T Akimoto, H Katoh, Y Kitamoto, K Shirai, M Shioya, T Nakano
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 64 (5) 1360 - 1366 0360-3016 2006/04 [Refereed][Not invited]
     
    Purpose: To evaluate the advantages of anatomy-based inverse optimization (IO) in planning high-close-rate (HDR) brachytherapy. Methods and Materials: A total of 114 patients who received HDR brachytherapy (9 Gy in two fractions) combined with hypofractionated external beam radiotherapy (EBRT) were analyzed. The dose distributions of HDR brachytherapy were optimized using geometric optimization (GO) in 70 patients and by anatomy-based 10 in the remaining 44 patients. The correlation between the dose-volume histogram parameters, including the urethral dose and the incidence of acute genitourinary (GU) toxicity, was evaluated. Results: The averaged values of the percentage of volume receiving 80-150% of the prescribed minimal peripheral dose (V-80-V-150) of the urethra generated by anatomy-based 10 were significantly lower than the corresponding values generated by GO. Similarly, the averaged values of the minimal dose received by 5-50% of the target volume (D-5-D-50) obtained using anatomy-based IO were significantly lower than those obtained using GO. Regarding acute toxicity, Grade 2 or worse acute GU toxicity developed in 23% of all patients, but was significantly lower in patients for whom anatomy-based IO (16%) was used than in those for whom GO was used (37%), consistent with the reduced urethral dose (p < 0.01). Conclusion: The results of this study suggest that anatomy-based 10 is superior to GO for dose optimization in HDR brachytherapy for prostate cancer. (c) 2006 Elsevier Inc.

MISC

  • 下顎骨区域切除術後に放射線治療計画CT撮影時の大開口により誘発された顎関節脱臼の1例.
    武者 篤, 熊澤 琢也, 吉本 由哉, 阿部 孝憲, 水上 達治, 白井 克幸, 齋藤 淳一, 大野 達也, 中野 隆史, 菅野 勇樹, 小川 将, 横尾 聡  歯科放射線  in press-  2018  [Not refereed][Not invited]
  • 重粒子線治療を受けた頭頸部腫瘍患者のQOLの定量化
    小此木 みなみ, 中村 真美, 柳澤 雅江, 今井 裕子, 武者 篤, 白井 克幸, 齋藤 淳一, 大野 達也, 中野 隆史  The Kitakanto Medical Journal  67-  (4)  379  -379  2017/11  [Not refereed][Not invited]
  • Propensity-scoreを用いたI期肺癌に対する定位放射線治療と炭素線治療の比較
    阿部 孝憲, 齋藤 淳一, 小松 秀一郎, 白井 克幸, 中野 隆史, 大野 達也  The Kitakanto Medical Journal  67-  (4)  381  -381  2017/11  [Not refereed][Not invited]
  • 同時期にX線または重粒子線で定位放射線治療を施行したI期肺癌症例の遡及的解析
    齋藤 淳一, 白井 克幸, 水上 達治, 阿部 孝憲, 大野 達也, 中野 隆史  日本癌治療学会学術集会抄録集  55回-  P155  -2  2017/10  [Not refereed][Not invited]
  • 粒子線治療の現状と方向性 肺癌治療後の孤立性リンパ節転移に対する重粒子線治療成績
    白井 克幸, 齋藤 淳一, 阿部 孝憲, 大野 達也, 中野 隆史  肺癌  57-  (5)  370  -370  2017/09  [Not refereed][Not invited]
  • I期肺癌に対する重粒子線治療における線量分布の頑健性に関する検証
    齋藤 淳一, 白井 克幸, 大野 達也, 中野 隆史  肺癌  57-  (5)  558  -558  2017/09  [Not refereed][Not invited]
  • 【腫瘍に対する放射線治療-高度化・個別化治療へ-】 放射線治療の有害事象と予防・支持療法 急性期有害事象
    白井 克幸, 齋藤 淳一, 中野 隆史  日本臨床  75-  (8)  1273  -1277  2017/08  [Not refereed][Not invited]
  • 頭頸部粘膜悪性黒色腫に対する重粒子線治療
    白井 克幸, 齋藤 淳一, 武者 篤, 阿部 孝憲, 小林 大二郎, 高安 幸弘, 紫野 正人, 豊田 実, 近松 一朗, 横尾 聡, 大野 達也, 中野 隆史  頭頸部癌  43-  (2)  182  -182  2017/05  [Not refereed][Not invited]
  • 強度変調放射線治療における口腔粘膜炎発症線量の検討
    武者 篤, 白井 克幸, 齋藤 淳一, 阿部 孝憲, 横尾 聡, 近松 一朗, 大野 達也, 中野 隆史  頭頸部癌  43-  (2)  236  -236  2017/05  [Not refereed][Not invited]
  • 櫻井 みずき, 高安 幸弘, 紫野 正人, 坂倉 浩一, 白井 克幸, 斎藤 淳一, 大野 達也, 中野 隆史, 近松 一朗  日本耳鼻咽喉科学会会報  120-  (4)  629  -629  2017/04  [Not refereed][Not invited]
  • Atsushi Musha, Jun-ichi Saitoh, Katsuyuki Shirai, Yoshiki Kubota, Hirofumi Shimada, Takanori Abe, Yuka Komatsu, Shuichiro Komatsu, Tatsuya Ohno, Takashi Nakano, Satoshi Yokoo  Physics and Imaging in Radiation Oncology  3-  1-4.  2017  [Not refereed][Not invited]
  • 局所進行肺癌(T2b〜T4N0M0)に対する重粒子線治療成績
    白井 克幸, 齋藤 淳一, 阿部 孝憲, 大野 達也, 中野 隆史  肺癌  56-  (6)  560  -560  2016/11  [Not refereed][Not invited]
  • X線または炭素イオン線で定位放射線治療を施行したI期肺癌症例についての遡及的解析
    齋藤 淳一, 白井 克幸, 大野 達也, 中野 隆史  肺癌  56-  (6)  560  -560  2016/11  [Not refereed][Not invited]
  • 特徴的なリンパ節転移を認めた、上眼瞼Merkel細胞癌の1例
    土田 圭祐, 齋藤 淳一, 白井 克幸, 武者 篤, 水上 達治, 阿部 孝憲, 川嶋 基敬, 深田 恭平, 大野 達也, 中野 隆史  The Kitakanto Medical Journal  66-  (4)  298  -298  2016/11  [Not refereed][Not invited]
  • 肺癌の気管再発に対しCyberKnifeで再照射を行った1例
    岩永 素太郎, 齋藤 淳一, 佐藤 浩央, 野田 真永, 小林 大二郎, 阿部 孝憲, 白井 克幸, 中野 隆史  The Kitakanto Medical Journal  66-  (4)  304  -305  2016/11  [Not refereed][Not invited]
  • 骨軟部 臨床試験・研究 小児・AYA世代の切除非適応骨軟部腫瘍症例に対する重粒子線治療成績
    清原 浩樹, 岡本 雅彦, 齋藤 淳一, 岡野 奈緒子, 柴 徳生, 村田 裕人, 入江 大介, 白井 克幸, 大野 達也, 荒川 浩一, 中野 隆史, 群馬大学重粒子線治療小児腫瘍専門部会  日本癌治療学会学術集会抄録集  54回-  MS30  -5  2016/10  [Not refereed][Not invited]
  • 肺 肺・縦隔の難治性腫瘍に対する集学的治療 T2a非小細胞肺癌に対する炭素イオン線治療ならびにCyberKnifeによる線量分布の比較
    岩永 素太郎, 齋藤 淳一, 小林 大二郎, 阿部 孝憲, 白井 克幸, 島田 博文, 野田 真永, 大野 達也, 中野 隆史  日本癌治療学会学術集会抄録集  54回-  WS58  -3  2016/10  [Not refereed][Not invited]
  • 頭頸・口腔 頭頸部がんに対する治療戦略 頭頸部非扁平上皮癌(腺癌)の炭素イオン線治療成績に関する多施設共同遡及的解析
    齋藤 淳一, 小藤 昌志, 出水 祐介, 末藤 大明, 大野 達也, 辻 比呂志, 沖本 智昭, 塩山 善之, 白井 克幸, 根本 建二, 中野 隆史, 鎌田 正  日本癌治療学会学術集会抄録集  54回-  WS80  -3  2016/10  [Not refereed][Not invited]
  • 頭頸部重粒子線治療時の口腔粘膜表面線量モデルによる急性期口腔粘膜炎の推移
    武者 篤, 島田 博文, 白井 克幸, 齋藤 淳一, 阿部 孝憲, 小林 大二郎, 横尾 聡, 近松 一朗, 大野 達也, 中野 隆史  日本癌治療学会学術集会抄録集  54回-  P1  -9  2016/10  [Not refereed][Not invited]
  • 下咽頭癌に対する放射線治療成績
    白井 克幸, 齋藤 淳一, 武者 篤, 阿部 孝憲, 小林 大二郎, 高安 幸弘, 紫野 正人, 豊田 実, 近松 一朗, 大野 達也, 中野 隆史  日本癌治療学会学術集会抄録集  54回-  P67  -7  2016/10  [Not refereed][Not invited]
  • 同時化学重粒子線治療により完全奏効が得られた口腔悪性黒色腫の一例
    重田 有香, 齋藤 淳一, 白井 克幸, 武者 篤, 阿部 孝憲, 横尾 聡, 大野 達也, 中野 隆史  日本癌治療学会学術集会抄録集  54回-  P67  -10  2016/10  [Not refereed][Not invited]
  • 武者 篤, 白井 克幸, 齋藤 淳一, 渋谷 圭, 大野 達也, 中野 隆史, 高山 優, 横尾 聡  歯科放射線  56-  (1)  39  -41  2016/09  [Not refereed][Not invited]
     
    67歳女。右下顎歯肉癌に対して右根治的頸部郭清術変法・右下顎区域切除術・大胸筋皮弁およびチタンプレートによる再建術を施行した。術後4ヵ月に左顎下リンパ節後発転移に対して左根治的頸部郭清術変法を施行し、術後化学療法併用放射線療法を施行した。照射終了後に誤嚥性肺炎を生じMEPM投与を開始したが、X線で両肺野に浸潤影を認めた。追加のCTで両肺野にすりガラス状陰影、内部に気管支透亮像を認め、中葉や左肺下葉背側等には濃厚な浸潤病変を認めた。誤嚥性肺炎を契機とした急性呼吸促迫症候群に合致する所見であり、喀痰培養検査にてMRSAが起炎菌の誤嚥性肺炎であることが判明した。MEPMにバンコマイシンを追加し、更に好中球エラスターゼ阻害剤投与、ステロイドパルス療法も開始し、以後の集中治療室での治療により呼吸状態は徐々に改善して一般病棟へ転棟した。3年以上経過の現在まで腫瘍の再発・転移はなく、呼吸状態も安定している。
  • DAV化学療法併用重粒子線照射による鼻副鼻腔悪性黒色腫の治療成績
    高橋 克昌, 岡本 彩子, 新國 摂, 近松 一朗, 白井 克幸, 齋藤 淳一, 大野 達也, 中野 隆史  日本鼻科学会会誌  55-  (3)  484  -484  2016/09  [Not refereed][Not invited]
  • 頭頸部腺癌に対する炭素イオン線治療成績の多施設共同遡及的解析
    齋藤 淳一, 小藤 昌志, 出水 祐介, 末藤 大明, 大野 達也, 辻 比呂志, 沖本 智昭, 塩山 善之, 白井 克幸, 根本 建二, 中野 隆史, 鎌田 正  頭頸部癌  42-  (2)  208  -208  2016/05  [Not refereed][Not invited]
  • I〜IVB期下咽頭癌に対する放射線治療成績
    白井 克幸, 齋藤 淳一, 武者 篤, 阿部 孝憲, 小林 大二郎, 高安 幸弘, 紫野 正人, 豊田 実, 近松 一朗, 大野 達也, 中野 隆史  頭頸部癌  42-  (2)  254  -254  2016/05  [Not refereed][Not invited]
  • 【がん放射線療法Update 2016】 最前線の研究治療 重粒子線治療
    白井 克幸, 大野 達也  医学のあゆみ  257-  (1)  25  -28  2016/04  [Not refereed][Not invited]
     
    重粒子線治療は、良好な線量分布に加え高い生物学的効果を示し、従来X線抵抗性と考えられていた腫瘍に対しても優れた局所制御率が報告されている。現在、治療施設は世界各国に10施設存在し、わが国では5施設と世界最多の数を誇っており、その治療技術や開発において指導的役割を果たしている。これまで、重粒子線治療の有効性は単施設による報告に限られていたが、近年多施設共同前向き試験の準備が進み、より高いエビデンスの創生が期待される。また、あらたな粒子線治療技術としてスキャンニング照射法、回転ガントリーが研究・開発され、より高精度で自由度の高い治療ができるようになってきている。本稿では、重粒子線治療の概要、これまでに報告されている臨床成績、ならびに今後の展望について概説する。(著者抄録)
  • 小児ならびにAYA世代腫瘍に対する放射線療法の進歩 小児・AYA世代の骨軟部腫瘍に対する炭素イオン線治療の成績
    清原 浩樹, 岡本 雅彦, 齋藤 淳一, 岡野 奈緒子, 村田 裕人, 白井 克幸, 柴 徳生, 大野 達也, 荒川 浩一, 中野 隆史, 群馬大学重粒子線治療小児腫瘍専門部会  日本小児血液・がん学会雑誌  52-  (4)  164  -164  2015/10  [Not refereed][Not invited]
  • 高橋 克昌, 西岡 由樹, 近松 一朗, 白井 克幸, 齋藤 淳一, 大野 達也, 中野 隆史  日本鼻科学会会誌  54-  (3)  479  -479  2015/09  [Not refereed][Not invited]
  • 白井 克幸, 中野 隆史  Radioisotopes  64-  (6)  416  -421  2015/06  [Not refereed][Not invited]
  • 岡野 奈緒子, 高草木 陽介, 尾池 貴洋, 齋藤 淳一, 鈴木 義行, 中野 隆史, 白井 克幸, 大野 達也  The Kitakanto Medical Journal  65-  (2)  167  -167  2015/05  [Not refereed][Not invited]
  • III期肺癌症例に対する重粒子線治療とX線治療計画の比較
    岩永 素太郎, 齋藤 淳一, 高草木 陽介, 鈴木 義行, 中野 隆史, 白井 克幸, 大野 達也  The Kitakanto Medical Journal  65-  (2)  168  -168  2015/05  [Not refereed][Not invited]
  • 頭頸部非扁平上皮癌に対する炭素イオン線治療の治療成績
    齋藤 淳一, 白井 克幸, 武者 篤, 大野 達也, 中野 隆史, 高安 幸弘, 紫野 正人, 豊田 実, 近松 一朗, 横尾 聡  頭頸部癌  41-  (2)  224  -224  2015/05  [Not refereed][Not invited]
  • 高安 幸弘, 紫野 正人, 豊田 実, 新国 摂, 高橋 克昌, 近松 一朗, 斎藤 淳一, 白井 克幸, 大野 達也, 中野 隆史  日本耳鼻咽喉科学会会報  118-  (4)  498  -498  2015/04  [Not refereed][Not invited]
  • 呼吸器 肺癌重粒子線治療後の局所再発に対するサルベージ手術の検討
    大沢 郁, 清水 公裕, 永島 宗晃, 大瀧 容一, 尾林 海, 矢澤 友弘, 齋藤 淳一, 白井 克幸, 藤田 敦, 竹吉 泉  日本外科学会定期学術集会抄録集  115回-  RS  -13  2015/04  [Not refereed][Not invited]
  • 清原浩樹, 岡本雅彦, 齋藤淳一, 岡野奈緒子, 村田裕人, 白井克幸, 柴徳生, 大野達也, 荒川浩一, 中野隆史  日本小児血液・がん学会雑誌(Web)  52-  (4)  164(J‐STAGE)  2015  [Not refereed][Not invited]
  • 重粒子線治療で二次性膜性腎症によるネフローゼ症候群を制御できた肺腺癌の1例
    阿久澤 有, 山口 央, 渡辺 裕輔, 藤野 節, 斉藤 淳一, 白井 克幸, 大野 達也, 中野 隆史, 小林 国彦  日本内科学会関東地方会  611回-  58  -58  2014/12  [Not refereed][Not invited]
  • 白井 克幸, 齋藤 淳一, 川嶋 基敬, 高草木 陽介, 柴 慎太郎, 武者 篤, 深田 恭平, 大野 達也, 高安 幸弘, 高橋 克昌, 近松 一郎, 中野 隆史  臨床放射線  59-  (10)  1357  -1364  2014/10  [Not refereed][Not invited]
     
    強度変調放射線治療を施行した中咽頭癌11例(全男、中央値67歳)の成績を報告した。臨床病期分類はstage IIIが3例、IVが8例であった。全例導入化学療法が施行され、10例には同時化学療法low dose cisplatin+docetaxelを行った。観察期間中央値11ヵ月で、照射野内再発および遠隔転移は認めず、有害事象はgrade 2以上の皮膚炎55%、粘膜炎91%、口内乾燥64%で、晩期毒性で潰瘍などの問題はなかった。血液毒性はgrade 2以上の白血球減少55%、貧血36%、血小板減少18%で、grade 4以上は認めなかった。全例の健側耳下腺の線量は平均25.6Gy、患側は37.7Gyであった。急性期の口内乾燥はgrade 0が1例、1が3例、2が7例であったが、grade 2の7例中6例は治療終了後1〜10ヵ月にgrade 1以下へ改善し、治療後6ヵ月でのgrade 2は11%、1年では0%となった。
  • 重粒子線治療を施行したI期原発性肺癌における治療前SUVmax(FDG-PET)の予後への影響
    白井 克幸, 齋藤 淳一, 岡野 奈緒子, 大野 達也, 中野 隆史  肺癌  54-  (5)  549  -549  2014/10  [Not refereed][Not invited]
  • IIIA期非小細胞肺癌に対する放射線治療計画における炭素イオン線とX線の線量分布の比較について
    齋藤 淳一, 白井 克幸, 岡野 奈緒子, 河村 英将, 大野 達也, 中野 隆史  肺癌  54-  (5)  550  -550  2014/10  [Not refereed][Not invited]
  • 頭頸部重粒子線治療における急性期口腔粘膜炎の発症時期に関する臨床的検討
    武者 篤, 島田 博文, 白井 克幸, 齋藤 淳一, 横尾 聡, 近松 一朗, 鈴木 義行, 大野 達也, 中野 隆史  日本口腔科学会雑誌  63-  (4)  340  -341  2014/09  [Not refereed][Not invited]
  • 頭頸部重粒子線治療における口腔粘膜炎発症線量の解析
    武者 篤, 島田 博文, 白井 克幸, 齋藤 淳一, 横尾 聡, 近松 一朗, 鈴木 義行, 大野 達也, 中野 隆史  The Kitakanto Medical Journal  64-  (3)  294  -294  2014/08  [Not refereed][Not invited]
  • 重粒子線治療後に局所再発した原発性肺腺癌の1切除例
    大沢 郁, 清水 公裕, 永島 宗晃, 大滝 容一, 尾林 海, 竹吉 泉, 齋藤 淳一, 白井 克幸, 上野 学  肺癌  54-  (4)  231  -231  2014/08  [Not refereed][Not invited]
  • 肺がん治療戦略のUp to Date 肺がんにおける感受性研究と新治療 肺癌に対する粒子線(陽子線、重粒子線)治療の展望
    大野 達也, 白井 克幸, 斉藤 淳一, 中野 隆史  日本癌治療学会誌  49-  (3)  721  -721  2014/06  [Not refereed][Not invited]
  • 視神経近接型頭頸部非扁平上皮癌症例に対する重粒子線治療計画
    齋藤 淳一, 白井 克幸, 高草木 陽介, 柴 慎太郎, 武者 篤, 鈴木 義行, 大野 達也, 中野 隆史  日本癌治療学会誌  49-  (3)  1061  -1061  2014/06  [Not refereed][Not invited]
  • 頭頸部重粒子線治療における急性期口腔粘膜炎の発症時期に関する臨床的検討
    武者 篤, 島田 博文, 白井 克幸, 齋藤 淳一, 高草木 陽介, 横尾 聡, 近松 一朗, 鈴木 義行, 大野 達也, 中野 隆史  日本癌治療学会誌  49-  (3)  2705  -2705  2014/06  [Not refereed][Not invited]
  • 中咽頭癌に対する強度変調放射線治療による口腔乾燥低減
    白井 克幸, 齋藤 淳一, 高草木 陽介, 柴 慎太郎, 武者 篤, 川嶋 基敬, 深田 恭平, 鈴木 義行, 大野 達也, 中野 隆史  日本癌治療学会誌  49-  (3)  2706  -2706  2014/06  [Not refereed][Not invited]
  • 視神経近接型頭頸部非扁平上皮癌症例に対する重粒子線治療計画の検討
    齋藤 淳一, 白井 克幸, 武者 篤, 高草木 陽介, 大野 達也, 中野 隆史  頭頸部癌  40-  (2)  177  -177  2014/05  [Not refereed][Not invited]
  • 局所進行中咽頭癌に対する化学療法併用強度変調放射線治療
    白井 克幸, 齋藤 淳一, 武者 篤, 岡野 奈緒子, 鈴木 義行, 大野 達也, 紫野 正人, 豊田 実, 高安 幸弘, 近松 一郎, 中野 隆史  頭頸部癌  40-  (2)  196  -196  2014/05  [Not refereed][Not invited]
  • 群馬大学における頭頸部領域腺様嚢胞癌に対する重粒子線治療の短期治療成績
    高安 幸弘, 紫野 正人, 豊田 実, 近松 一朗, 斎藤 淳一, 白井 克幸, 大野 達也, 中野 隆史  頭頸部癌  40-  (2)  224  -224  2014/05  [Not refereed][Not invited]
  • 頭頸部重粒子線治療における急性期口腔粘膜炎の発症時期に関する臨床的検討
    武者 篤, 島田 博文, 白井 克幸, 齋藤 淳一, 高草木 陽介, 横尾 聡, 近松 一朗, 鈴木 義行, 大野 達也, 中野 隆史  頭頸部癌  40-  (2)  245  -245  2014/05  [Not refereed][Not invited]
  • 高安 幸弘, 紫野 正人, 豊田 実, 高橋 克昌, 近松 一朗, 斎藤 淳一, 白井 克幸, 大野 達也, 中野 隆史  日本耳鼻咽喉科学会会報  117-  (4)  454  -454  2014/04  [Not refereed][Not invited]
  • 頭頸部重粒子線治療における急性期口腔粘膜炎と粘膜表面線量との関連
    武者 篤, 島田 博文, 白井 克幸, 齋藤 淳一, 岡野 奈緒子, 横尾 聡, 大野 達也, 中野 隆史  日本口腔科学会雑誌  63-  (1)  150  -150  2014/01  [Not refereed][Not invited]
  • X線および炭素イオン線による肺定位照射後の放射線肺臓炎体積のDVH解析
    岡野 奈緒子, 斎藤 淳一, 白井 克幸, 大野 達也, 中野 隆史  肺癌  53-  (5)  433  -433  2013/10  [Not refereed][Not invited]
  • I期肺野型肺癌に対する重粒子線(炭素イオン線)治療の初期治療経過
    齋藤 淳一, 白井 克幸, 岡野 奈緒子, 大野 達也, 中野 隆史, 江原 威  肺癌  53-  (5)  453  -453  2013/10  [Not refereed][Not invited]
  • 切除不能局所進行非小細胞肺癌におけるCDDP+S-1と胸部放射線同時併用療法の第I/II相試験
    解良 恭一, 富澤 由雄, 吉野 麗子, 吉井 明弘, 久田 剛志, 石塚 全, 前野 敏孝, 白井 克幸, 斎藤 淳一, 江原 威, 松浦 正名, 砂長 則明  肺癌  53-  (5)  484  -484  2013/10  [Not refereed][Not invited]
  • 阿部 孝憲, 江原 威, 原田 耕作, 白井 克幸, 塩谷 真里子, 鈴木 義行, 櫻井 英幸, 中野 隆史  Thermal Medicine  29-  (3)  63  -67  2013/09  [Not refereed][Not invited]
     
    多形性脂肪肉腫は脂肪肉腫の中で稀な組織型である。しばしば治療抵抗性を示し、予後不良であることが知られている。今回、大腿部に再々発した多形性脂肪肉腫に対して温熱放射線併用療法を施行し、良好な治療効果が得られたので報告する。症例は69歳男性。右大腿部原発の多形性脂肪肉腫に対し、腫瘍切除術、術後放射線治療(1回2Gy、総線量50Gy)が行われた。9ヵ月後、局所再発し、再切除が施行された。さらに1年後、再々発を来たし、温熱療法(週1回、計5回)が施行された。しかし、治療効果は認められず、腫瘍はさらに増大したため、放射線治療(1回2Gy、総線量40Gy)と温熱療法(週1回、計4回)の併用療法が施行された。腫瘍は著明に縮小し、2年後に死亡するまで局所は制御された。温熱放射線併用療法は手術不能の多形性脂肪肉腫に対する治療の選択肢となり得る。(著者抄録)
  • 末梢型I期肺癌に対する炭素イオン線治療
    齋藤 淳一, 白井 克幸, 岡野 奈緒子, 高草木 陽介, 鈴木 義行, 大野 達也, 中野 隆史  日本癌治療学会誌  48-  (3)  1171  -1171  2013/09  [Not refereed][Not invited]
  • 重粒子線治療を受けたがん患者のQOLアンケート評価(SF-8)の1年後の変化
    加藤 弘之, 北田 陽子, 白井 克幸, 野田 真永, 清原 浩樹, 齋藤 淳一, 小山 佳成, 鈴木 義行, 大野 達也, 中野 隆史  日本癌治療学会誌  48-  (3)  1175  -1175  2013/09  [Not refereed][Not invited]
  • I〜III期下咽頭癌に対する放射線治療成績
    白井 克幸, 齋藤 淳一, 岡野 奈緒子, 高草木 陽介, 高橋 健夫, 鈴木 義行, 大野 達也, 中野 隆史  日本癌治療学会誌  48-  (3)  3023  -3023  2013/09  [Not refereed][Not invited]
  • 阿部 孝憲, 齋藤 淳一, 白井 克幸, 吉本 由哉, 鈴木 義行, 中野 隆史, 大野 達也, 高橋 克昌, 近松 一朗  The Kitakanto Medical Journal  63-  (3)  277  -278  2013/08  [Not refereed][Not invited]
  • 竹村 仁男, 上野 学, 増渕 裕朗, 神戸 将彦, 北原 信介, 青木 史暁, 前野 敏孝, 須賀 達夫, 白井 克幸, 齋藤 淳一  気管支学  35-  (Suppl.)  S191  -S191  2013/05  [Not refereed][Not invited]
  • 頭頸部重粒子線治療における急性期口腔粘膜炎と粘膜表面線量との関連
    武者 篤, 島田 博文, 白井 克幸, 齋藤 淳一, 岡野 奈緒子, 横尾 聡, 近松 一朗, 大野 達也, 中野 隆史  頭頸部癌  39-  (2)  188  -188  2013/05  [Not refereed][Not invited]
  • 頭頸部非扁平上皮癌に対する炭素イオン線治療の治療経験
    齋藤 淳一, 白井 克幸, 武者 篤, 大野 達也, 中野 隆史, 紫野 正人, 豊田 実, 近松 一朗, 横尾 聡  頭頸部癌  39-  (2)  188  -188  2013/05  [Not refereed][Not invited]
  • I〜III期下咽頭癌に対する放射線治療成績
    白井 克幸, 齋藤 淳一, 岡野 奈緒子, 吉本 由哉, 桑子 慧子, 高橋 健夫, 鈴木 義行, 大野 達也, 紫野 正人, 豊田 実, 近松 一朗, 中野 隆史  頭頸部癌  39-  (2)  223  -223  2013/05  [Not refereed][Not invited]
  • 高安 幸弘, 紫野 正人, 豊田 実, 高橋 克昌, 近松 一朗, 斎藤 淳一, 白井 克幸, 大野 達也, 中野 隆史  日本耳鼻咽喉科学会会報  116-  (4)  524  -524  2013/04  [Not refereed][Not invited]
  • T. Kaminuma, H. Katoh, H. Ishikawa, T. Tamaki, K. Shirai, H. Matsui, K. Itoh, T. Ohno, K. Suzuki, T. Nakano  INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS  84-  (3)  S397  -S397  2012/11  [Not refereed][Not invited]
  • J. Saitoh, K. Shirai, T. Ohno, Y. Yoshimoto, A. Musya, H. Katoh, S. Noda, T. Tamaki, Y. Suzuki, T. Nakano  INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS  84-  (3)  S835  -S835  2012/11  [Not refereed][Not invited]
  • 鼻腔・副鼻腔悪性黒色腫に対する重粒子線治療における生理的鼻粘膜腫脹による飛程の変化について
    齋藤 淳一, 白井 克幸, 武者 篤, 大野 達也, 中野 隆史  頭頸部癌  38-  (2)  227  -227  2012/05  [Not refereed][Not invited]
  • 阿部 孝憲, 齋藤 淳一, 白井 克幸, 野田 真永, 久保 亘輝, 中川 彰子, 大野 達也, 中野 隆史  The Kitakanto Medical Journal  62-  (2)  229  -229  2012/05  [Not refereed][Not invited]
  • 【画像誘導放射線治療の進歩】 粒子線治療における画像誘導放射線治療の重要性 自己放射化画像を含め
    齋藤 淳一, 大野 達也, 白井 克幸, 加藤 弘之, 鈴木 義行, 中野 隆史  臨床放射線  57-  (4)  510  -517  2012/04  [Not refereed][Not invited]
  • 前立腺癌におけるinter-fractional organ motionに関連する因子の検討
    福島 斉, 田嶋 正義, 樋口 雅則, 相澤 健太郎, 町田 貴志, 遠藤 廣, 村田 和俊, 白井 克幸, 北本 佳住, 玉木 義雄  The Kitakanto Medical Journal  61-  (3)  418  -418  2011/08  [Not refereed][Not invited]
  • 4D-CTを用いた呼吸同期照射の初期経験 ITVの体積と動きに関する検討
    村田 和俊, 白井 克幸, 北本 佳住, 樋口 啓子, 玉木 義雄  The Kitakanto Medical Journal  61-  (3)  418  -418  2011/08  [Not refereed][Not invited]
  • 当院における前立腺癌の放射線治療成績
    白井 克幸, 村田 和俊, 北本 佳住, 樋口 啓子, 玉木 義雄  The Kitakanto Medical Journal  61-  (3)  420  -420  2011/08  [Not refereed][Not invited]
  • 前立腺癌に対するIMRTの初期経験 臨床的な立場から
    岡本 雅彦, 北本 佳住, 白井 克幸, 牛島 弘毅, 樋口 啓子, 玉木 義雄, 樋口 雅則, 福島 斉, 斉藤 優子, 田島 正義, 茂木 利雄, 町田 貴志, 遠藤 廣  The Kitakanto Medical Journal  61-  (3)  425  -425  2011/08  [Not refereed][Not invited]
  • Katsuyuki Shirai, Kamalakannan Palanichamy, Krishnan Thirumoorthy, Disha Patel, Nicolaus Gordon, Arnab Chakravarti  CANCER RESEARCH  71-  2011/04  [Not refereed][Not invited]
  • 野中 哲生, 櫻井 英幸, 石川 仁, 村田 真澄, 塩谷 真里子, 白井 克幸, 原島 浩一, 中野 隆史, 中島 政信, 加藤 広行, 桑野 博行  The Kitakanto Medical Journal  61-  (1)  97  -98  2011/02  [Not refereed][Not invited]
  • Y. Suzuki, M. Hino, K. Shirai, Y. Yoshida, T. Mizui, K. Hanamura, T. Shirao, T. Nakano  INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS  81-  (2)  S718  -S718  2011  [Not refereed][Not invited]
  • Pseudo-Progression Phenomenon During Temozolomide Combination Chemoradiotherapy for Malignant Glioma.
    Yoshiyuki Suzuki, Wael Saleem, Yumi Satoh, Masaru Wakatsuki, Katsuyuki Shirai, Ken-ichi Sugawara, Shin-ei Noda, Masahiko Okamoto, Yuhei Yoshimoto, Takashi Nakano  IRPC  12-  (2)  123  -127  2011  [Not refereed][Not invited]
  • 脳神経細胞の放射線感受性
    鈴木 義行, 吉田 由香里, 白井 克幸, 岡本 雅彦, 工藤 滋弘, 中野 隆史  放射線生物研究  45-  (3)  236  -248  2010/09  [Not refereed][Not invited]
     
    初代神経細胞培養法(バンカー法・変法)によるラット神経細胞を用いた、正常脳神経細胞・組織の放射線感受性に関する著者等の最近の研究を中心に、以下の知見について概説した。1)神経細胞における放射線照射後のアポトーシス誘導、2)神経細胞とグリア細胞の放射線感受性、3)放射線照射が未成熟神経細胞の発達に及ぼす影響、4)脳切片組織での放射線照射後の変化。
  • 下葉肺癌に対する呼吸同期照射を用いた体幹部定位放射線治療の経験
    北本 佳住, 岡本 雅彦, 白井 克幸, 牛島 弘毅, 玉木 義雄  肺癌  49-  (5)  772  -772  2009/10  [Not refereed][Not invited]
  • 放射線照射が未成熟神経細胞に及ぼす影響
    岡本 雅彦, 鈴木 義行, 水井 利幸, 白井 克幸, 吉田 由香里, 野田 真永, Wael Al-Jahdari, 白尾 智明, 中野 隆史  神経組織の成長・再生・移植研究会学術集会プログラム・予稿集  24回-  58  -58  2009/06  [Not refereed][Not invited]
  • 培養切片を用いた正常小脳組織における放射線生物学的効果の検討
    吉田 由香里, 鈴木 義行, 白井 克幸, Al-Jahdari W.S, 浜田 信行, 舟山 知夫, 坂下 哲哉, 小林 泰彦, 小澤 瀞司, 中野 隆史  神経組織の成長・再生・移植研究会学術集会プログラム・予稿集  24回-  62  -62  2009/06  [Not refereed][Not invited]
  • 当院における前立腺癌に対する放射線療法の検討
    蓮見 勝, 武智 浩之, 清水 信明, 白井 克幸, 村田 和俊, 北本 佳住, 玉木 義雄  The Kitakanto Medical Journal  59-  (2)  216  -216  2009/05  [Not refereed][Not invited]
  • 食道癌における4D-CTの有用性について(第一報) 呼吸性移動の検討
    白井 克幸, 北本 佳住, 村田 和俊, 樋口 啓子, 玉木 義雄  日本医学放射線学会学術集会抄録集  68回-  S200  -S200  2009/02  [Not refereed][Not invited]
  • 限局型小細胞肺癌症例における癌胎児性抗原(CEA)高値と治療成績の関係
    北本 佳住, 白井 克幸, 村田 和俊, 樋口 啓子, 堀越 浩幸, 大屋 成之, 秋吉 司, 白須 昌代, 岡山 絢, 玉木 義雄  日本医学放射線学会学術集会抄録集  68回-  S309  -S309  2009/02  [Not refereed][Not invited]
  • 癌の放射線治療におけるPETCTの有用性
    村田 和俊, 白井 克幸, 樋口 啓子, 北本 佳住, 玉木 義雄  The Kitakanto Medical Journal  59-  (1)  72  -72  2009/02  [Not refereed][Not invited]
  • 当センターにおける呼吸同期システムを用いた定位放射線治療
    田嶋 正義, 福島 斉, 樋口 雅則, 相澤 健太郎, 町田 貴志, 遠藤 廣, 村田 和俊, 白井 克幸, 北本 佳住, 樋口 啓子, 玉木 義雄  The Kitakanto Medical Journal  59-  (1)  73  -73  2009/02  [Not refereed][Not invited]
  • 前立腺癌におけるCBCTを用いた生理的患者動態の検討
    福島 斉, 田嶋 正義, 樋口 雅則, 相澤 健太郎, 町田 貴志, 遠藤 廣, 村田 和俊, 白井 克幸, 北本 佳住, 樋口 啓子, 玉木 義雄  The Kitakanto Medical Journal  59-  (1)  73  -73  2009/02  [Not refereed][Not invited]
  • 治療計画装置とマニュアル法で求めたMU値の差異に関する検討
    村田 和俊, 白井 克幸, 樋口 啓子, 北本 佳住, 玉木 義雄  The Kitakanto Medical Journal  59-  (1)  73  -73  2009/02  [Not refereed][Not invited]
  • 渋谷 圭, 長谷川 正俊, 斉藤 淳一, 鈴木 義行, 北本 佳住, 白井 克幸, 秋元 哲夫, 中野 隆史, 石内 勝吾, 斉藤 延人, 栗原 秀行  The Kitakanto Medical Journal  59-  (1)  95  -96  2009/02  [Not refereed][Not invited]
  • 白井 克幸, 鈴木 義行, 岡本 雅彦, 水井 利幸, 吉田 由香里, 花村 健次, 白尾 智明, 中野 隆史  日本放射線影響学会大会講演要旨集  51回-  123  -123  2008/11  [Not refereed][Not invited]
  • 局所進行非小細胞肺癌の診断時腫瘍マーカー値と治療成績
    北本 佳住, 白井 克幸, 玉木 義雄, 湊 浩一, 佐藤 浩二, 鈴木 邦明  肺癌  48-  (5)  506  -506  2008/10  [Not refereed][Not invited]
  • 前立腺癌局所放射線治療後に骨盤内リンパ節転移をきたした2例
    白井 克幸, 北本 佳住, 樋口 啓子, 佐藤 友美, 玉木 義雄  The Kitakanto Medical Journal  58-  (3)  341  -341  2008/08  [Not refereed][Not invited]
  • 胃および十二指腸に同時発症したMALTリンパ腫の1例
    佐藤 友美, 白井 克幸, 北本 佳住, 樋口 啓子, 玉木 義雄, 五十嵐 忠彦, 村山 佳予子, 小島 勝  The Kitakanto Medical Journal  58-  (3)  341  -342  2008/08  [Not refereed][Not invited]
  • 喉頭がん(T2,T3)治療法の選択 切除・再建か放射線・化学療法か 当院におけるT2,T3喉頭癌の治療方法と治療成績
    玉木 義雄, 北本 佳住, 樋口 啓子, 白井 克幸, 佐藤 友美, 藤城 芳徳, 明石 健, 吉積 隆  頭頸部癌  34-  (2)  116  -116  2008/05  [Not refereed][Not invited]
  • 吉田 由香里, 鈴木 義行, 浜田 信行, 白井 克幸, Al-Jahdari Wael S, 舟山 知夫, 坂下 哲哉, 小林 泰彦, 小澤 瀞司, 中野 隆史  日本放射線影響学会大会講演要旨集  50回-  153  -153  2007/11  [Not refereed][Not invited]
  • 炭素ビームに対するニューロンの感受性:成長円錐虚脱法によるアプローチ(Neuronal sensitivity to carbon beams: Approach using growth cone collapse assay)
    Al-Jahdari Wael S, 鈴木 義行, 吉田 由香里, 浜田 信行, 野田 真永, 白井 克幸, 舟山 知夫, 坂下 哲哉, 小林 泰彦, 中野 隆史  日本放射線影響学会大会講演要旨集  50回-  153  -153  2007/11  [Not refereed][Not invited]
  • Tetsuo Nonaka, Hideyuki Sakurai, Hitoshi Ishikawa, Mariko Shioya, Masumi Murata, Katsuyuki Shirai, Koichi Harashima, Takeshi Ebara, Takashi Nakano, Hiroyuki Kato, Hiroyuki Kuwano  AMERICAN JOURNAL OF GASTROENTEROLOGY  102-  S138  -S138  2007/09  [Not refereed][Not invited]
  • II-III期食道癌に対する放射線治療成績
    村田 真澄, 野中 哲生, 桜井 英幸, 石川 仁, 白井 克幸, 塩谷 真里子, 原島 浩一, 江原 威, 中野 隆史, 加藤 広行, 桑野 博行  日本癌治療学会誌  42-  (2)  820  -820  2007/09  [Not refereed][Not invited]
  • 子宮頸癌放射線治療の3次元的治療計画パラメータと直腸有害事象の検討
    北本 佳澄, 樋口 啓子, 白井 克幸, 佐藤 友美, 西村 俊信, 玉木 義雄  日本放射線腫瘍学会誌  19-  (3)  221  -221  2007/09  [Not refereed][Not invited]
  • 子宮頸癌の経過観察におけるFDG-PETの有効性とその限界
    桜井 英幸, 鈴木 義行, 野中 哲生, 江原 威, 塩谷 真里子, 清原 浩樹, 加藤 弘之, 田巻 倫明, 白井 克幸, 原田 耕作, 秋元 哲夫, 中野 隆史  The Kitakanto Medical Journal  57-  (3)  272  -272  2007/08  [Not refereed][Not invited]
  • 村田 真澄, 樋口 啓子, 北本 佳住, 原島 浩一, 白井 克幸, 玉木 義雄  The Kitakanto Medical Journal  57-  (3)  281  -281  2007/08  [Not refereed][Not invited]
  • 肺癌の放射線治療計画における手計算法とSuper Position法の相違
    白井 克幸, 村田 真澄, 原島 浩一, 北本 佳住, 樋口 啓子, 玉木 義雄, 町田 貴志, 田子 明弘, 樋口 雅則, 遠藤 廣  The Kitakanto Medical Journal  57-  (3)  284  -284  2007/08  [Not refereed][Not invited]
  • 【がんの緊急病態と症状マネジメント】 がんの治療(放射線療法)に伴う緊急病態と対応 放射線肺臓炎
    北本 佳住, 白井 克幸, 村田 真澄, 玉木 義雄, 福田 淳子  看護技術  53-  (5)  474  -478  2007/04  [Not refereed][Not invited]
  • 【がんの緊急病態と症状マネジメント】 がんの治療(放射線療法)に伴う緊急病態と対応 放射線による腸管障害(放射線腸炎)
    玉木 義雄, 北本 佳住, 村田 真澄, 白井 克幸, 宮内 歩美  看護技術  53-  (5)  479  -484  2007/04  [Not refereed][Not invited]
  • 培養切片を用いた小脳における放射線生物学的効果の検討
    吉田 由香里, 鈴木 義行, 白井 克幸, Al-Jahdari Wael S, 中野 隆史, 浜田 信行, 小林 泰彦, 小澤 瀞司  The Kitakanto Medical Journal  57-  (1)  66  -66  2007/02  [Not refereed][Not invited]
  • T. Nakano, K. Shirai, T. Mizui, Y. Suzuki, M. Okamoto, Y. Yoshida, W. Al-Jahdari, K. Hanamura, T. Shirao  INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS  69-  (3)  S608  -S609  2007  [Not refereed][Not invited]
  • M. Okamoto, Y. Suzuki, K. Shirai, T. Mizui, Y. Yoshida, S. Noda, A. Wael, T. Shirao, T. Nakano  INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS  69-  (3)  S599  -S600  2007  [Not refereed][Not invited]
  • Effect of X-irradiation on dendritic spine morphology of hippocampal neurons
    Shirai K, Mizui T, Yoshida Y, Okamoto M, Suzuki Y, Hanamura K, Nakano T, Shirao T  Neuroscience Research (Supplement)  58-  (1)  S134  2007  [Refereed][Not invited]
  • III期非小細胞肺癌に対する同時併用放射線化学療法
    江原 威, 櫻井 英幸, 野中 哲生, 河村 英将, 石川 仁, 鈴木 義行, 加藤 弘之, 白井 克幸, 中山 優子, 中野 隆史  肺癌  46-  (5)  511  -511  2006/11  [Not refereed][Not invited]
  • 前立腺癌・高線量率組織内照射の治療計画におけるanatomy-based inverse optimizationによる尿道線量の低減効果
    加藤 弘之, 秋元 哲夫, 江原 威, 白井 克幸, 田巻 倫明, 原田 耕作, 桜井 英幸, 中野 隆史  日本放射線腫瘍学会誌  18-  (3)  169  -169  2006/09  [Not refereed][Not invited]
  • 脳膠芽腫におけるアポトーシス抑制因子Survivinの発現と予後への影響
    白井 克幸, 鈴木 義行, 野田 真永, 加藤 弘之, 野中 哲生, 桜井 英幸, 中野 隆史  日本癌学会総会記事  65回-  353  -353  2006/09  [Not refereed][Not invited]
  • 発達期神経細胞における放射線感受性に関する研究
    白井 克幸, 鈴木 義行, 風間 秀子, 町田 伸子, 中野 隆史, 水井 利幸, 白尾 智明, 浜田 信行, 和田 成一, 小林 泰彦, 舟山 知夫, 坂下 哲哉  The Kitakanto Medical Journal  56-  (3)  269  -269  2006/08  [Not refereed][Not invited]
  • 【前立腺がん放射線療法の進歩】 放射線治療の合併症・QOL評価・改善のための工夫 前立腺癌に対する外照射併用高線量率組織内照射後の急性反応 Geometrical optimizationとanatomy based inverse optimizationの比較
    秋元 哲夫, 加藤 弘之, 白井 克幸, 田巻 倫明, 原田 耕作, 山本 巧, 伊藤 一人, 鈴木 和浩, 中野 隆史  泌尿器外科  19-  (8)  975  -979  2006/08  [Not refereed][Not invited]
     
    前立腺癌に対する外照射併用高線量率組織内照射におけるanatomy based inverse optimization(AB-IO)の有効性を評価するため、急性尿路反応および尿道線量を指標にgeometrical optimization(GO)のみで最適化を行った症例と比較検討した。GO群70例、AB-IO群72例を対象とした。RTOG/EORTC toxicity criteriaによる急性反応の最適化方法別のgradingは、GO群:grade 0-1;44例、grade 2-3;26例、AB-IO群:grade 0-1;58例、grade 2-3;14例と、AB-IO群で有意にgrade 2-3の尿路系急性反応が少なく、尿道線量(尿道のV80〜V150)が有意にAB-IO群で低かった。Target coverageおよびconformal indexともにAB-IO群で良好であった。この結果からAB-IOは前立腺への線量を損なうことなく、尿道への線量を低下して急性反応を低減する有効な方法と考えられた。(著者抄録)
  • 温熱放射線療法が著効した再発脂肪肉腫の一例
    原田 耕作, 桜井 英幸, 鈴木 義行, 塩谷 真里子, 白井 克幸, 中野 隆史  日本ハイパーサーミア学会誌  22-  (2)  94  -94  2006/06  [Not refereed][Not invited]
  • Glioblastomaに対する通常分割照射後Boost照射の予後への影響
    白井 克幸, 鈴木 義行, 加藤 弘之, 中野 隆史, 長谷川 正俊  The Kitakanto Medical Journal  56-  (2)  195  -195  2006/05  [Not refereed][Not invited]
  • 神経細胞放射線感受性の発達期における変化
    白井 克幸, 水井 利幸, 鈴木 義行, 風間 秀子, 町田 信子, 小林 泰彦, 白尾 智明, 中野 隆史  神経組織の成長・再生・移植研究会学術集会プログラム・予稿集  21回-  44  -44  2006/05  [Not refereed][Not invited]
  • 前立腺癌の高線量率組織内照射治療計画時におけるanatomy-based inverse optimizationの有効性
    加藤 弘之, 秋元 哲夫, 江原 威, 白井 克幸, 田巻 倫明, 原田 耕作, 桜井 英幸, 中野 隆史  日本医学放射線学会学術集会抄録集  65回-  S163  -S163  2006/02  [Not refereed][Not invited]
  • 前立腺癌に対する高線量率組織内照射の治療成績と晩期有害事象
    秋元 哲夫, 加藤 弘之, 白井 克幸, 田巻 倫明, 江原 威, 中野 隆史  日本医学放射線学会学術集会抄録集  65回-  S163  -S164  2006/02  [Not refereed][Not invited]
  • Y. Suzuki, K. Shirai, T. Mizui, N. Hamada, S. Noda, T. Funayama, Y. Yoshida, Y. Kobayashi, T. Shirao, T. Nakano  INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS  66-  (3)  S591  -S591  2006  [Not refereed][Not invited]
  • Y. Yoshida, Y. Suzuki, A. Takeuchi, N. Hamada, K. Shirai, T. Funayama, T. Sakashita, Y. Kobayashi, S. Ozawa, T. Nakano  INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS  66-  (3)  S250  -S250  2006  [Not refereed][Not invited]
  • Katsuyuki Shirai, Toshiyuki Mizui, Yoshiyuki Suzuki, Yasuhiko Kobayashi, Takashi Nakano, Tomoaki Shirao  NEUROSCIENCE RESEARCH  55-  S120  -S120  2006  [Not refereed][Not invited]
  • T. Akimoto, H. Katoh, K. Shirai, K. Harada, K. Ito, T. Yamamoto, T. Nakano  INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS  66-  (3)  S387  -S388  2006  [Not refereed][Not invited]
  • WHO grade 3 gliomaにおける組織亜型と予後に関する解析
    白井 克幸, 鈴木 義行, 加藤 弘之, 桜井 英幸, 野中 哲生, 清原 浩樹, 塩谷 真里子, 秋元 哲夫, 長谷川 正俊, 中野 隆史  日本放射線腫瘍学会誌  17-  (Suppl.1)  130  -130  2005/10  [Not refereed][Not invited]
  • B細胞性リンパ腫における放射線療法の役割の検討
    長谷川 正俊, 塩谷 真里子, 鈴木 義行, 斉藤 淳一, 北本 佳住, 桜井 英幸, 白井 克幸, 中山 優子, 小島 勝, 中野 隆史  日本リンパ網内系学会会誌  45-  104  -104  2005/06  [Not refereed][Not invited]
  • 白井 克幸, 仲本 宗健, 若月 優, 鈴木 良彦  The Kitakanto Medical Journal  55-  (2)  181  -181  2005/05  [Not refereed][Not invited]
  • 脳原発悪性リンパ腫のメソトレキセート大量療法併用放射線療法は標準治療か?
    長谷川 正俊, 鈴木 義行, 石川 仁, 斉藤 淳一, 北本 佳住, 白井 克幸, 野田 真永, 桜井 英幸, 中野 隆史  日本放射線腫瘍学会誌  16-  (Suppl.1)  116  -116  2004/10  [Not refereed][Not invited]
  • 抗CD20抗体rituximab併用CHOP療法(R-CHOP療法)の適応と課題
    野田 真永, 鈴木 義行, 斉藤 淳一, 北本 佳住, 白井 克幸, 秋元 哲夫, 中山 優子, 中野 隆史  日本放射線腫瘍学会誌  16-  (Suppl.1)  151  -151  2004/10  [Not refereed][Not invited]
  • 食道癌放射線治療におけるCYFRA21-1の臨床的有用性
    若月 優, 仲本 宗健, 鈴木 良彦, 白井 克幸  日本放射線腫瘍学会誌  16-  (Suppl.1)  178  -178  2004/10  [Not refereed][Not invited]
  • I期食道癌に対する放射線治療成績
    石川 仁, 桜井 英幸, 中山 優子, 原島 浩一, 山川 通隆, 斉藤 吉弘, 岡本 雅彦, 白井 克幸, 原田 耕作, 長谷川 正俊, 中野 隆史  The Kitakanto Medical Journal  54-  (3)  248  -249  2004/08  [Not refereed][Not invited]
  • 脳・眼球内に再燃を認めた悪性リンパ腫の1例
    白井 克幸, 斉藤 淳一, 北本 佳住, 長谷川 正俊, 中野 隆史  The Kitakanto Medical Journal  54-  (3)  250  -250  2004/08  [Not refereed][Not invited]
  • 両側性肺癌に対して放射線治療を行った一例
    吉田 大作, 中山 優子, 石川 仁, 白井 克幸, 北本 佳住, 長谷川 正俊, 中野 隆史, 玉木 義雄  The Kitakanto Medical Journal  54-  (2)  165  -165  2004/05  [Not refereed][Not invited]
  • 診断に苦慮した中縦隔腫瘍の一例
    白井 克幸, 中山 優子, 石川 仁, 北本 佳住, 吉田 大作, 斉藤 淳一, 長谷川 正俊, 中野 隆史, 田中 司玄文, 柏原 賢治  The Kitakanto Medical Journal  54-  (2)  165  -165  2004/05  [Not refereed][Not invited]
  • 中枢神経系外に再然を認めた脳悪性リンパ腫の一例
    渋谷 圭, 長谷川 正俊, 斉藤 淳一, 鈴木 義行, 北本 佳住, 白井 克幸, 秋元 哲夫, 中野 隆史, 石内 勝吾, 斉藤 延人, 栗原 秀行  The Kitakanto Medical Journal  54-  (2)  171  -171  2004/05  [Not refereed][Not invited]
  • 診断に苦慮した中縦隔腫瘍の1例
    白井 克幸, 中山 優子, 石川 仁, 北本 佳住, 吉田 大作, 斉藤 淳一, 長谷川 正俊, 中野 隆史, 田中 司玄文, 柏原 賢治  肺癌  44-  (2)  127  -127  2004/04  [Not refereed][Not invited]
  • 脳原発悪性リンパ腫の放射線治療 メソトレキセート併用例と非併用例の比較
    長谷川 正俊, 石川 仁, 斉藤 淳一, 鈴木 義行, 北本 佳住, 白井 克幸, 渋谷 圭, 桜井 英幸, 中山 優子, 中野 隆史  日本医学放射線学会雑誌  64-  (2)  S256  -S256  2004/02  [Not refereed][Not invited]
  • 悪性リンパ腫の病勢判別における可溶性インターロイキン-2レセプターの有用性
    斉藤 淳一, 長谷川 正俊, 北本 佳住, 石川 仁, 白井 克幸, 鈴木 義行, 桜井 英幸, 秋元 哲夫, 中山 優子, 中野 隆史  日本医学放射線学会雑誌  64-  (2)  S261  -S261  2004/02  [Not refereed][Not invited]
  • 中枢神経系胚細胞性腫瘍の放射線治療
    長谷川 正俊, 鈴木 義行, 斉藤 淳一, 白井 克幸, 北本 佳住, 桜井 英幸, 石川 仁, 中山 優子, 中野 隆史  日本放射線腫瘍学会誌  15-  (Suppl.1)  148  -148  2003/10  [Not refereed][Not invited]


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.